Functional characterization of the transcription factor ZEB1 in epithelial to mesenchymal transition and cancer progression by Sultan, Aneesa
 
 





Titel der Dissertation 
 
Functional Characterization of the Transcription Factor ZEB1 in 
Epithelial to Mesenchymal Transition  
and Cancer Progression 
 
 
angestrebter akademischer Grad 
Doktor/in der Naturwissenschaften (Dr. rer.nat.) 
 
Verfasserin / Verfasser:     Mag. Aneesa Sultan 
Matrikel-Nummer:              0448631 
Dissertationsgebiet            Biologie/Genetik 
(lt. Studienblatt): 













and special thanks go to… 
 
…My supervisor Professor Andreas Eger for introducing me to his interesting world of science 
and providing support and help whenever needed. I am thankful to Professor Roland Foisner for 
providing me the opportunity to work in his lab. 
 
...Higher Education Commission (HEC) Pakistan for providing me the financial support to 
pursue my PhD studies and Austrian Exchange Service (ÖAD) for facilitating my higher studies 
here in Austria. 
 
…All members of the Foisner lab for great working atmosphere, in particular Kirsten, Luise, 
Harald, Nana, Andi, Mirta and Ursula. 
 
…All my Pakistani friends in Vienna especially Arjumand, Saadia, Sheeba, Fareeha, Tazeen, 
Mamoona, Mariam and Shazia Farooq. I share very sweet memories of our stay in Vienna and 
our trips all over Europe. Besides, your encouragements have been a pure source of motivation 
for me especially during the write-up phase. 
 
…The kind support and understanding from my husband Amir Jamal Malik, and to the love of 
our life; our daughter Aanya Sahar Malik who brought fresh air into our lives. 
 
…The Supplications and prayers made by my elders and well wishers in Pakistan. And to my 
dear sisters and brothers who missed me and were badly missed during my stay in Vienna.  
 
…My deepest appreciation goes to my parents for their unconditional love and care. Their 
confidence in my abilities helped me achieve this milestone in my life. For this and much more, I 


































Table of Contents 
1 Abstract ....................................................................................................................................... 1 
2 Introduction ................................................................................................................................ 3 
2.1 Cancer: Basic Facts ............................................................................................................... 3 
2.2 Epithelial to Mesenchymal Transition (EMT) ...................................................................... 4 
2.2.1 EMT in Development ..................................................................................................... 5 
2.2.2 EMT as a Physiological Response to Injury .................................................................. 6 
2.2.3 Pathological EMT .......................................................................................................... 6 
2.3 Loss of Cell Polarity in EMT ................................................................................................ 8 
2.4 Major Signaling Pathways in EMT....................................................................................... 9 
2.5 Regulation of Cadherins During EMT ................................................................................ 12 
2.5.1 E-Cadherin in EMT and Tumor Progression .............................................................. 13 
2.5.2 Structural Organisation of E-Cadherin Gene and Its Promoter ................................. 14 
2.5.3 Transcriptional Repression of E-cadherin................................................................... 15 
2.6 The Transcription Factor ZEB1 .......................................................................................... 17 
2.7 Aims of the Thesis .............................................................................................................. 22 
3  Materials and Methods ........................................................................................................... 23 
3.1  siRNA - Mediated Knockdown of ZEB1 and SNAI1 ....................................................... 23 
3.1.1 Transfection of Cells .................................................................................................... 23 
3.1.2 Extraction of Total RNA............................................................................................... 24 
3.1.3 Reverse Transcriptase PCR ......................................................................................... 24 
3.2 Chromatin ImmunoPrecipitation (ChIP) ............................................................................. 25 
3.3 β-Galactosidase Reporter Assay ......................................................................................... 26 
3.3 Cell Migration and Invasion Assays ................................................................................... 27 
3.4 Generation of Stable Clones ............................................................................................... 29 
 
 
3.4.1 Stable Expression of E-Cadherin in MDA-MB-321 ..................................................... 29 
3.4.2 Stable Expression of SNAI1 in MCF7 Cells ................................................................ 29 
3.5 Immunological Assays ........................................................................................................ 30 
3.5.1 Immunofluorescence .................................................................................................... 30 
3.5.2 Western Blot Analysis .................................................................................................. 30 
3.5.3 Immunohistochemical Staining of Paraffin Sections ................................................... 30 
3.5.4 Immunofluorescence of Paraffin Sections ................................................................... 31 
4 Results ....................................................................................................................................... 33 
4.1 Published Results ................................................................................................................ 33 
4.1.1 (Submitted for publication) .......................................................................................... 33 
ZEB1 regulates E-Cadherin, cell proliferation and cell invasion in human breast cancer 
cell lines, implicating epigenetic modifications for E-Cadherin repression. ....................... 33 
4.1.2 The transcription factor ZEB1 (dEF1) promotes tumour cell dedifferentiation by 
repressing master regulators of epithelial polarity .............................................................. 34 
4.1.3 The transcription factor ZEB1 (dEF1) represses Plakophilin 3 during human cancer 
progression ........................................................................................................................... 63 
4.1.4 The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in 
cancer .................................................................................................................................... 71 
4.2 Unpublished results ............................................................................................................. 79 
4.2.1 Stable ZEB1 knock down using shRNA in MDA-MB-231 cells ................................... 79 
4.2.2 Overexpression of ZEB1 domains as dominant negative approach ............................ 81 
4.2.3 ZEB1 in MCF7 cells expressing a variant of SNAI1 (MCF7-6SA) ............................. 83 
5 Discussion.................................................................................................................................. 85 






Epithelial to mesenchymal transition (EMT) is implicated in the progression of primary tumours 
towards metastasis and is likely caused by a pathological activation of transcription factors 
regulating EMT in embryonic development. To analyse EMT-causing pathways in 
tumourigenesis, transcriptional targets of the E-cadherin repressor ZEB1 in invasive human 
cancer cells were identified. We show that ZEB1 repressed multiple key determinants of 
epithelial differentiation and cell–cell adhesion, including the cell polarity genes Crumbs3, 
HUGL2, PKP3 and Pals1-associated tight junction protein. ZEB1 associated with their 
endogenous promoters in vivo, and strongly repressed promoter activities in reporter assays. 
ZEB1 downregulation in undifferentiated cancer cells by RNA interference was sufficient to 
upregulate expression of these cell polarity genes on the RNA and protein level, to re-establish 
epithelial features and to impair cell motility in vitro.  
In human colorectal cancer, ZEB1 expression was limited to the tumour–host interface and was 
accompanied by loss of intercellular adhesion and tumour cell invasion. EMT-inducing 
transcriptional repressor ZEB1 promotes colorectal cancer cell metastasis and loss of cell 
polarity. Thereby, ZEB1 suppresses the expression of cell polarity factors, in particular of Lgl2, 
which was found to be reduced in colorectal and breast cancers.  
In invasive ductal and lobular breast cancer, upregulation of ZEB1 was stringently coupled to 
cancer cell dedifferentiation. The invasion potential of MDA-MB-231, a highly invasive breast 
cancer cell line, is shown to be under the control of ZEB1. Over-expression of ZEB1down-
regulates and relocalizes E-Cadherin in MCF7 breast cancer cells; moreover, ZEB1 over-
expression results in reduced proliferation rate of these cells. Most importantly, we show that 
ZEB1 mediated downregulation of E-cadherin involves chromatin modifications. Markers of 
transcriptionally active chromatin Acetylated H3 and Acetylated H4 were increased upon ZEB1 
knock down in MDA-MB-231 cells, while repressive marks like H3K9me2 and H3K27me2 
were obseverved to disappear in the same cells.  
Collectively, the data presented in this thesis show that ZEB1 represents a key player in 







2.1 Cancer: Basic Facts 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. 
If the spread is not controlled, it can result in death. Cancer is caused by both external factors 
(infectious organisms, tobacco, chemicals, and radiation) and internal factors (inherited 
mutations, hormones, immune conditions, and mutations that occur from metabolism). These 
causal factors may act together or in sequence to initiate or promote carcinogenesis. Ten or more 
years often pass between exposure to external factors and detectable cancer. Cancer is treated 
with surgery, radiation, chemotherapy, hormone therapy, biological therapy, and targeted therapy 
(AmericanCancerSociety, 2009).  




The vast catalog of cancer cell genotypes is a manifestation of six essential alterations in 
cell physiology that collectively dictate malignant growth as depicted in Figure 1. Each 
of these physiologic changes represents the successful breaking of an anticancer defense 
mechanism hardwired into cells and tissues. Hanahan and Weinberg proposed that these 
six capabilities are shared in common by most and perhaps all types of human tumors. 
One in eight deaths worldwide occurs due to cancer. Worldwide, cancer causes more 
deaths than AIDS, tuberculosis, and malaria combined. Cancer is the second leading 
cause of death in economically developed countries (following heart diseases) and the 
third leading cause of death in developing countries (following heart diseases and 
diarrhoeal diseases) (Garcia M, 2007). Breast cancer is the most common cancer 
affecting women. For every 100 women, 12 will develop the disease and five are likely to 
die from it (Parkin et al., 2005). Metastases are the cause of 90% human cancer deaths 
(Mehlen and Puisieux, 2006). To metastasize, cancer cells must break many fundamental 
rules of normal cellular behavior. They detach from neighboring cells, move freely on 
their own, enter the bloodstream and survive there, and finally exit into new tissue and 
colonize it. The mechanism involved in this metastatic spread is epithelial-to-
mesenchymal transition (EMT). 
2.2 Epithelial to Mesenchymal Transition (EMT) 
Epithelial cells establish close contacts with their neighbors and an apicobasal axis of 
polarity through the sequential arrangement of adherens junctions, desmosomes, and tight 
junctions. The epithelial cell layer maintains global communication through gap 
junctional complexes, has limited movement of epithelial cells to the two-dimensional 
space of the epithelial plane and it remains separated from adjacent tissues by a basal 
lamina. Conversely, mesenchymal or stromal cells are loosely organized in a three-
dimensional ExtraCellular Matrix (ECM) and comprise connective tissues adjacent to 
epithelia. 
“Epithelial to mesenchymal transition (EMT) comprises of the cellular and molecular 
processes by which epithelial cells lose cell–cell interactions and apico-basal polarity at 
the same time as acquiring mesenchymal and migratory properties”. It was first 
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recognized by (Greenburg and Hay, 1982) to be a central process in early embryonic 
morphogenesis. 
Core elements of EMT include reduction of cell–cell adherence via the transcriptional 
repression and delocalization of cadherins (adherens junctions), occludin and claudin 
(tight junctions), and desmoplakin (desmosomes). The cadherin supporting molecule β-
catenin is often lost from the cell membrane and translocates to the nucleus to participate 
in EMT signaling events (Eger et al., 2000; Klymkowsky, 2005). Circumferential F-actin 
fibres of the cytoskeleton are replaced by a network of stress fibers, at the tips of which 
ECM adhesion molecules (including integrins, paxillin, focal adhesion kinase) localize. 
These changes potentially allow cells to separate, lose the apico-basal polarity typical of 
epithelial cells, and gain a more variable cell shape and changeable cell adhesions, all of 
which facilitate cell movement. Expression of epithelial intermediate filaments, 
containing cytokeratins, is typically reduced and the equivalent mesenchymal filament 
protein vimentin increased. Matrix metalloproteases (MMPs) such as MMP-1, -2, -3, -7, 
and -14 are frequently upregulated, potentially enabling cells to detach from each other 
(via E-cadherin cleavage) and to penetrate the basement membrane. ECM synthesis 
changes from basal lamina to interstitial forms. These genetic alterations, along with 
changes in cellular shape to a more elongated, fibroblast appearance with front-back 
polarity signify EMT (Hay, 1995; Hugo et al., 2007). Crucially, cells following EMT 
show increased motile potential. 
2.2.1 EMT in Development 
Most adult tissues and organs arise from a series of conversions of epithelial cells to 
mesenchymal cells, through the epithelial to mesenchymal transition (EMT) and the 
reverse process (mesenchymal to epithelial transition [MET]). Several rounds of EMT 
and MET are necessary for the final differentiation of specialized cell types and 
acquisition of complex three-dimensional structure of internal organs. Accordingly, these 
sequential rounds are referred to as primary, secondary, and tertiary EMT. Examples of 
primary EMT include those evident during mammalian implantation, gastrulation in 
various metazoans, and in the neural crest formation of all vertebrates. Secondary EMT 
occurs during the formation of somites, palate, pancreas, liver, and reproductive tracts, 
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whereas heart develops through three successive cycles of EMT and MET (Thiery et al., 
2009). A plethora of signaling pathways and agents are known to induce EMT in 
numerous cellular contexts in different organisms and they provide important basis for 
understanding of EMT in disease. 
2.2.2 EMT as a Physiological Response to Injury 
Processes similar to EMT also occur as a physiological response to injury. During wound 
healing, keratinocytes at the border of the wound recapitulate part of the EMT process. 
They appear to acquire an intermediate phenotype known as the “metastable” state, 
which allows them to move while maintaining loose contacts rather than migrating as 
individual cells. Snail2 expression in keratinocytes at the migratory front influences this 
state, as its inactivation or overexpression compromises or accelerates wound healing, 
respectively (Arnoux et al., 2008). In addition, in each menstrual cycle the ovarian 
surface epithelium undergoes an EMT-like process during postovulatory wound healing. 
This EMT is induced by epidermal growth factor (EGF) and involves the activation of 
metalloproteases and of ILK and ERK kinases (Ahmed et al., 2007). 
2.2.3 Pathological EMT 
EMT not only occurs during embryonic development or as a physiological response to 
injury, but is also an important element in cancer progression and other pathologies that 
involve organ degeneration, such as fibrosis. At the cellular level, pathological EMTs are 
very similar to physiological EMTs in that they are governed by similar signaling 
pathways, regulators, and effector molecules. 
2.2.3.1 Organ Fibrosis 
In fibrotic tissues, myofibroblasts accumulate and secrete an excessive amount of 
collagen that is deposited as fibers, thereby compromising organ function and leading to 
its failure. Fibrosis had been thought to originate through the pathological activation of 
interstitial fibroblasts that convert to myofibroblasts to form the fibrotic collagen 
network. However, elegant cell tracing studies have shown that a significant portion of 
these myofibroblasts arise from the conversion of epithelial cells through an EMT 
process (Iwano et al., 2002). Initially demonstrated in differentiated cells of renal tubules 
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and ducts, it is now clear that lens epithelium, endothelium, hepatocytes, and 
cardiomyocytes can all undergo EMT and contribute significantly to tissue fibrosis. 
2.2.3.2 Cancer Progression 
Over the last decade, evidence has mounted for EMT as the means through which solid 
tissue epithelial cancers invade and metastasize. However, demonstrating this potentially 
rapid and transient process in vivo has proven difficult and data connecting the relevance 
of this process to tumor progression is still somewhat limited and controversial (Hugo et 
al., 2007; Thiery et al., 2009).  
Numerous observations support the idea that EMT has a central role in tumour 
progression. During progression to metastatic competence, carcinoma cells acquire 
mesenchymal gene-expression patterns and properties. This results in changed adhesive 
properties, and the activation of proteolysis and motility, which allows the tumour cells to 
metastasize and establish secondary tumours at distant sites (Sleeman, 2000). In tissue 
culture this progression is accompanied by partial or complete EMT, and induction of 
EMT in many carcinoma cell lines results in the acquisition of metastatic properties in 
vivo (Huber et al., 2004; Yang et al., 2004). It has recently been suggested that the 
acquisition of mesenchymal markers and properties during tumour progression simply 
reflects genomic instability and that EMT does not occur in tumours (Tarin et al., 2005). 
However, it is highly unlikely that the coordinated and complex gene-expression patterns 
that are required to endow tumour cells with the mesenchymal properties that are 
required for metastasis could arise through random mutations as a result of genomic 
instability. Rather, it is more likely that genomic instability changes the expression of 
important factors that regulate EMT. SNAI1, for example, regulates the expression of 
many EMT-associated genes in colorectal carcinoma cells (De Craene et al., 2005a). In 
this regard, it is striking that the same signaling pathways that regulate developmental 
EMT are also activated during tumour progression. It is also clear that the EMT that is 
observed in cultured tumour cells converts into increased metastatic potential in vivo 
(Huber et al., 2004; Yang et al., 2004), arguing against the idea that EMT in tumour cells 
is a tissue-culture artifact without biological significance (Thiery and Sleeman, 2006).  
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Recently, systemic spread has been detected from early lesions in HER-2 transgenic mice 
and in human ductal carcinoma suggesting that metastasis is not necessarily a late event 
in tumour progression (Husemann et al., 2008). More importantly, individual 
mesenchymal cells derived from epithelial tumour cells after EMT are very difficult to 
distinguish from stromal cells or other tumor-associated fibroblasts. The description of 
cords or small aggregates of tumor cells extending or detaching from the tumor mass into 
the adjacent stroma have recently provided morphological evidence of EMT at invasive 
fronts of human tumours (Prall, 2007). Similarly, in colon carcinoma, EMT occurs at the 
invasive front and produces single migratory cells that lose E-cadherin expression. This is 
concomitant with deregulation of the Wnt pathway and a selective loss of the basement 
membrane (Brabletz et al., 2001). This phenomenon is recapitulated by other solid 
tumours, as the invasive fronts in papillary thyroid carcinoma or in some breast 
carcinoma reveal an EMT expression profile, and those in cervical carcinoma show 
increased vimentin and loss of E-cadherin (Thiery et al., 2009). Direct in vivo imaging 
has also yielded evidence of EMT in cancer progression (Wyckoff et al., 2007). 
2.3 Loss of Cell Polarity in EMT 
The loss of cell polarity is a crucial step for EMT. Polarity is largely regulated by a 
conserved set of proteins known as partition-defective (PAR) proteins, which are required 
for organizing the apico-basal polarity of epithelial cells and for the establishment and 
maintenance of apical junction. The PAR3/PAR6/aPKC complex localizes selectively at 
the apical junction and the apical plasma membrane; whereas Par1, resides at the 
basolateral membranes of epithelia. Mutual antagonistic interactions between these two 
complexes results in the formation of cellular and functional asymmetry within the cell. 
In addition to the Par complex, the lateral resided CRUMBS/PALS1/PATJ complex and 
the tight junction associated SCRIBBLE/DLG/LGL complex, are also required for the 
formation of cell polarity. During the initial stage of epithelial cell contact, spot-like 
adherens junctions first appear at the tips of protrusions that contain Ecadherin, nectins, 
junctional adhesion molecule (JAM), and protein ZO-1. E-cadherin mediates initial 
intercellular adhesion, which is substantially strengthened after its connection to the actin 
cytoskeleton through α- and β-catenin. These connections mature into adherent junctions 
and promote the formation of tight junctions, which further anchors to the Par complex to 
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establish cell polarity (Wu and Zhou, 2008). SNAIL1 alters epithelial cell polarity by 
repressing the transcription of Crumbs3 and abolishing the localization of both Par and 
Crumbs complexes at the junctions (Whiteman et al., 2008). Similarly, we have shown 
that ZEB1 directly represses the transcription of cell polarity genes, including Crumbs3, 
Pals1- associated tight junction proteins (PATJ), and the member of the Scribble complex 
Lethal giant larvae (Lgl2) (Aigner et al., 2007b; Spaderna et al., 2008). TGFβ contributes 
to the loss of cell polarity during EMT in two ways, through the canonical pathway by 
inducing Snail and ZEB genes expression and through a noncanonical pathway that 
involves the downregulation of Par3 expression and the Par6-mediated degradation of 
RhoA and local alteration of the actin cytoskeleton ((Ozdamar et al., 2005; Wang et al., 
2008). 
2.4 Major Signaling Pathways in EMT 
Many signaling pathways trigger EMT in both embryonic development as well as in 
normal and transformed cell lines. The signaling pathways include those triggered by 
different members of the TGFβ superfamily, Wnt, Notch, Hedgehog, EGF, FGF, HGF, 
HIF, and many others. The vast majority of the signaling pathways known to trigger 
EMT converge at the induction of the E-cadherin repressors. 
TGFβ is a ubiquitous cytokine, which is well known for its ability to inhibit proliferation 
of epithelial cells (Siegel and Massague, 2003). Somatic mutations abrogating TGFβ- 
signaling are found in various gastrointestinal cancers, thus confirming its importance as 
a tumor suppressor. Intriguingly, the pathway is also able to strongly promote cancer cell 
invasion and metastatic dissemination during late stage carcinogenesis (Bachmann et al., 
2005). TGFβ is capable of initiating and maintaining EMT in a variety of biological 
systems and pathophysiological contexts by activating major signaling pathways and 
transcriptional regulators integrated in extensive signaling networks (Zavadil and 
Bottinger, 2005). TGFβ has been shown to regulate the Actin cytoskeleton and the 
stability of adherens junctions using RhoA-dependent mechanisms (Bhowmick et al., 
2001a; Bhowmick et al., 2001b). Multiple effectors within the PDGF Receptor signaling 
pathway were also found upregulated during TGFβ induced EMT (Jechlinger et al., 
2003). Induction of EMT in fully polarized murine mammary epithelial cells (EpH4) by 
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inducible c-Fos Estrogen receptor (FosER) oncoprotein engrosses loss of E-cadherin 
expression, nuclear translocation of β-Catenin, and autocrine production of TGFβ. 
Additionally, β- Catenin/LEF/Tcf (T cell factor) and TGFβ Smad-dependent signaling 
activities are upregulated, possibly co-regulating mesenchymal-specific gene expression 
during EMT (Eger et al., 2004). In the majority of tested epithelial cell types, TGFβ-
signaling cooperates with oncogenic Ras or RTKs in order to cause EMT and metastasis 
(Seton-Rogers et al., 2004; Siegel and Massague, 2003; Ueda et al., 2004; Xie et al., 
2004).                                               
                                    
Fig. 2: Overview of the molecular networks that regulate EMT. A selection of the 
signaling pathways that are activated by regulators of EMT and a limited representation of their 
crosstalk is illustrated. Activation of receptor tyrosine kinases (RTKs) is known to induce EMT in 
several epithelial cell types and in vivo, but it is now clear that the EMT process often requires 
co-activation of integrin receptors. The role of TGFβ signaling in EMT is established for a 
limited number of normal and transformed cell lines, whereas in vivo data has indicated a mutual 
regulation of the TGFβ and NOTCH pathways during EMT. There is now increasing evidence 
that other signaling pathways could have an important role in EMT, including G-protein-coupled 
receptors. Matrix metalloproteinases (MMPs) can also trigger EMT through as-yet-undefined 




Noticeably, effectors upstream or downstream of Ras could substitute for activated RTKs 
or Ras in working with TGFβ-signaling to cause EMT. These pathways can be activated 
by specific, often developmental signals, but are also controlled by crosstalk between 
each other, and with RTK/Ras and TGFβ/BMP signaling (Huber et al., 2005). 
Several signaling pathways, being essential for stem cell function and early development, 
such as the Wnt/β-Catenin, Notch and Hedgehog signaling have a major impact on EMT 
during development and cancer progression (Thiery, 2003). For instance components of 
the Hedgehog pathway are mutated in a few, specific tumor types (Karhadkar et al., 
2004; Pasca di Magliano and Hebrok, 2003). Concerning the Wnt/ β-Catenin pathway, β-
Catenin levels and stability, and its function via LEF/Tcf transcriptional regulators, are 
enhanced if E-cadherin is degraded or transcriptionally repressed, or if Glycogen 
Synthase Kinase 3β (GSK-3β) activity is suppressed by activated PI3K downstream of 
RTKs or Ras (Eger et al., 2000; Grunert et al., 2003; Nelson and Nusse, 2004; Stockinger 
et al., 2001). Moreover, GSK-3β was found to downregulate SNAI1 by two independent 
mechanisms: transcriptional repression (Bachelder et al., 2005), and phosphorylation 
leading to export from the nucleus and destruction via the ubiquitin-proteasome pathway 
(Zhou et al., 2004). 
The Notch pathway can act in a tumor-suppressive or tumor-promoting fashion, like 
TGFβ-signaling, depending on cellular context and whether cooperating oncogenes are 
present or not (Radtke and Raj, 2003). Notch induces SNAI1 during heart development 
(Timmerman et al., 2004) and is also required for neural crest induction and 
differentiation (Cornell and Eisen, 2005). Recent studies propose SNAI2 as a target of 
Notch signaling (High et al., 2007; Leong et al., 2007; Niessen et al., 2008). Interestingly, 
Notch directly promotes SNAI1 activation during hypoxia through the binding of its 
processed intracellular form to the SNAI1 promoter and the activation of Lox2 
expression by the hypoxia factor 1 (HIF-1), thereby stabilizing the SNAI1 protein 
(Sahlgren et al., 2008). 
Vascular endothelial growth factor (VEGF) signaling promotes EMT in pancreatic and 
breast tumor cells by inducing SNAI1 and Twist expression (Wanami et al., 2008; Yang 
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et al., 2006a). Interestingly, SNAI1 can induce VEGF expression in epithelial cells 
(Peinado et al., 2004), and they are coexpressed during peritoneal fibrosis (Zhang et al., 
2008). Hence, a regulatory loop between angiogenesis and EMT may contribute to tumor 
progression. 
Platelet-derived growth factor (PDGF) stimulates EMT in colon carcinoma cells through 
the nuclear translocation of β-catenin in a Wnt-independent manner (Yang et al., 2006b). 
A similar process may also be at work during EGF and TGFβ- induced EMT (Gotzmann 
et al., 2006). EGF is known to induce EMT by promoting E-cadherin endocytosis (Lu et 
al., 2003), but it can also induce the expression of both SNAI1 and Twist, repressing E-
cadherin transcription among other targets (Lee et al., 2008; Lo et al., 2007). 
The NFκB pathway is also emerging as an important regulator of EMT in carcinoma cell 
lines and mesothelial fibrosis, acting through the induction of SNAI1 transcription (Julien 
et al., 2007; Strippoli et al., 2008) and protein stabilization (Wu et al., 2009). The 
importance of this pathway is evidenced by the blocking of EMT elicited by 
nondestructible IkB, a NFκB inhibitor (Huber et al., 2004; Thiery et al., 2009) 
2.5 Regulation of Cadherins During EMT 
The cadherin superfamily of Ca2+ dependent homophilic adhesion molecules plays a 
critical role in regulating cell-cell interactions. During EMT, the expression of different 
cadherins is highly dynamic, since they are associated with the morphogenesis, 
establishment and/or maintenance of different tissues. For example, N-cadherin is 
frequently up-regulated during the transition from an epithelial to a mesenchymal 
phenotype (Derycke and Bracke, 2004), [although there are clear exceptions to this rule 
(Duband et al., 1995)]. Because of this, the switch between E- and N-cadherin expression 
is thought to contribute to EMT and MET; e.g., in the mouse primitive streak (Nakagawa 
and Takeichi, 1995), cardiogenesis, and somitogenesis (Takeichi, 1988; Takeichi, 1995).  
Modifications of cell-cell interactions occur during carcinogenesis, where the disruption 
of cell-cell contacts is one of the key events in tumour progression. During the last 
decade, the expression of cadherins during tumour progression has been the subject of 
extensive studies, the majority of which have focused on the role of E-cadherin. The loss 
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of E-cadherin expression and/or function has been observed during tumour progression of 
most carcinomas and this has been related to the induction of EMT which frequently 
occurs during carcinoma invasion (Peinado et al., 2004a; Thiery, 2002). 
2.5.1 E-Cadherin in EMT and Tumor Progression 
A hallmark of epithelial to mesenchymal transition is decreased expression of Ecadherin, 
and it has been hypothesized that transcriptional repressors that control the expression of 
E-cadherin in development may also regulate the expression of Ecadherin during 
tumorigenesis (Thiery, 2002). E-cadherin production is maintained in most differentiated 
tumors, including carcinomas of the skin, head and neck, breast, liver, lung, prostate and 
colon, but there seems to be an inverse correlation between Ecadherin levels and cancer 
grade. 
E-cadherin has been viewed as a classical suppressor of invasion because E-cadherin is 
responsible for stable cell-cell adhesion in epithelial tissues and inhibits cell migration 
(Hajra et al., 2002; Larue et al., 1996; Okegawa et al., 2002; Peinado et al., 2004a). 
Tumor cells lose or acquire invasive properties when E-cadherin-mediated adhesion is 
increased or inhibited, respectively (Behrens et al., 1989; Frixen et al., 1991; Vleminckx 
et al., 1991). Ectopic expression of E-cadherin in transgenic mouse and Drosophila tumor 
models prevented tumor cell invasion and metastasis (Pagliarini and Xu, 2003; Perl et al., 
1998). 
Mammary epithelial cells expressing a fusion protein of c-Fos and the Estrogen receptor 
(EpFosER) undergo EMT upon Estradiol-dependent activiation of c-Fos. These 
mesenchymal cells can also cause metastatic neoplasia in mice (A. Eger, unpublished 
observations). Downregulation of E-cadherin during EMT caused translocation of β-
Catenin into the nucleus resulting in activation of the β-Catenin/LEF-1 (lymphocyte 
enhancer factor) signaling pathway (Eger et al., 2000). Re-expression of Ecadherin in 
mesenchymal cells reduced β-Catenin/LEF transcription activity, negatively affected cell 
proliferation in an adhesion-independent manner, and established an epitheloid phenotype 
lacking a typical epithelial polarization (Stockinger et al., 2001). Thus, E-cadherin 
downregulation may play multiple roles in tumorigenesis, including loss of cell-cell 
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adhesion, activation of β-Catenin signaling, increase in migratory potential and cell 
proliferation. 
Downregulation of E-cadherin function in tumors can occur via several mechanisms. 
Missense, splice site, and truncation mutations have all been reported in the E-cadherin 
gene (Peinado et al., 2004a). An alternative mechanism for inactivating the adhesive 
function of E-cadherin in tumor cells is to disrupt the connection between the Cadherin 
and the cytoskeleton. For example, mutations in β-Catenin that disrupt its binding to α-
Catenin result in a non-adhesive phenotype (Wheelock and Johnson, 2003). Moreover, 
mutations in the gene that encodes α-Catenin effectively inactivate E-cadherin function 
by not allowing the Cadherin complex to associate with the cytoskeleton (Wheelock and 
Johnson, 2003). In addition, posttranscriptional and posttranslational regulatory 
mechanisms interfering with E-cadherin dependent intercellular adhesion in tumor cells 
have also been identified (D'Souza-Schorey, 2005). 
Posttranslational regulation of E-cadherin can occur via charge of cell surface 
glycosaminoglycans (Kowalczyk et al., 1994) or through truncation of the cell adhesion 
molecule, which is an inactivating event significantly increased in localized prostate 
tumors (Birchmeier et al., 1993; Rashid et al., 2001). 
Taken these data together, E-cadherin can be considered as an invasion suppressor gene 
and loss of E-cadherin function is thought to be one of the most important events during 
carcinoma progression (Birchmeier and Behrens, 1994; Birchmeier and Birchmeier, 
1994). 
2.5.2 Structural Organisation of E-Cadherin Gene and Its Promoter 
The human E-cadherin gene (CDH1) is located at the 16q22.1 locus and is comprised of 
16 exons, spanning 99 Kb of genomic DNA. The mouse E-cadherin gene (cdh1) has a 
similar exon-intron organisation and is located on chromosome 8. The Ecadherin 
promoter lacks a TATA box, but contains a CCAAT-box at -65 and a GC-rich region at -
40. In addition, an E-pal element has been found in the murine promoter at -86 that 
consists of two E-boxes (E-box1 and 2), of which E-box1 is conserved in human 
promoter as well. Further analyses identified two additional E-boxes in the human 
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promoter (E-box3 and 4), of which E box3 is present in mouse sequence as well at -30. 
The fourth E-box at position +22 in the human gene is not conserved. Mutually 
conserved E-boxes 1 and 3 show 100% sequence homology in human and mouse 
promoters (Peinado et al., 2004a) (Fig. 2). 
 
Fig. 3: Schematic representation of the E-cadherin promoter region and E-box 
sequences in mouse and human. The E-cadherin promoter region is represented with its 
representative proximal control elements in the proximal region. Binding of identified 
factors to the different E-boxes is shown in the lower part. Observe the high degree of 
conservation of E-box 1 and E-box 3 in the lowermost part. (Adapted from Peinado et al., 
2004) 
 
2.5.3 Transcriptional Repression of E-cadherin 
Although E-cadherin gene is mutated in specific subtypes of cancers, the incidence of 
such mutations in carcinogenesis is low (Berx et al., 1995; Guilford et al., 1998; Risinger 
et al., 1994). On the other hand, loss of E-cadherin in cancer cells often involves 
transcriptional repression (Eger et al., 2005; Peinado et al., 2004a; Strathdee, 2002). 
Transcriptional repression may include epigenetic modifications, involving CpG island 
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hypermethylation of the E-cadherin regulatory promoter (Grady et al., 2000; Graff et al., 
1995), as well as repression by specific transcription factors, including SNAI1 (Batlle et 
al., 2000; Cano et al., 2000), Slug (Bolos et al., 2003; Hajra et al., 2002) and the helix-
loop-helix factor E12/E47 (Bolos et al., 2003; Peinado et al., 2004a; Perez-Moreno et al., 
2001). 
Silencing of E-cadherin expression via hypermethylation of CpG islands in the Ecadherin 
promoter has been demonstrated in human carcinomas, including breast, prostate, 
bladder, colon, and oral cancers (Chang et al., 2002; Graff et al., 2000; Kanazawa et al., 
2002; Nass et al., 2000; Ribeiro-Filho et al., 2002). (Graff et al., 2000) showed that CpG 
methylation of the E-cadherin promoter in invasive ductal carcinoma of the breast begins 
early in tumorigenesis, prior to the invasive state (Wheelock and Johnson, 2003). 
The first evidence for E-cadherin-specific transcriptional repressors was provided by the 
group of Amparo Cano (Cano et al., 2000; Peinado et al., 2007), who used one-hybrid 
screening with the E-pal sequence as bait. This screening identified transcription factors 
SNAI1, Slug and E12/E47, which were subsequently proven to be potent repressors of E-
cadherin expression. In addition, the two homologous ZEB1 and SIP1/ZEB2 zinc-finger 
factors were both proven to be direct repressors of E-cadherin transcription (Comijn et 
al., 2001; Eger et al., 2005). SNAI1, Slug, ZEB1 and ZEB2 actively repress transcription 
by recruiting transcriptional corepressors, such as CtBP and mSinA (Peinado et al., 2007; 
Shi et al., 2003a; van Roy and Berx, 2008). All of these repressors also silence E-
cadherin by binding to the proximal E-boxes, although some differences are observed 
between the human and mouse promoters. While the factors that act on the mouse 
promoter seem to preferentially interact with the E-pal element (including SNAI1, Slug 
and E47) (Bolos et al., 2003; Cano et al., 2000; Perez-Moreno et al., 2001), in the human 
promoter either all three E-boxes or E-box 1 and 3 appear to be required for the 
interaction of SNAI1/Slug or ZEB1/ZEB2, respectively (Batlle et al., 2000; Comijn et al., 
2001; Grooteclaes and Frisch, 2000; Hajra et al., 2002; Peinado et al., 2004a). 
Conversely, there are other E-cadherin repressors such as Twist, Goosecoid, E2.2, and 
FoxC2 which repress E-cadherin transcription indirectly. Twist, Goosecoid, and FoxC2 
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are all associated with the metastatic potential. (Sobrado et al., 2009; Yang and 
Weinberg, 2008). 
2.6 The Transcription Factor ZEB1 
The transcription factor ZEB1 (also known as δ-crystalline enhancer-binding factor 1 / 
δEF1, TCF8, AREB6, ZFH-1, NIL-2A, MEB1, BZP, ZFHEP and ZFHX1A), a member 
of the ZEB protein family, is a complex transcription factor that has several functional 
domains. It is featured by two widely separated arrays of C2H2-type Zn-finger domains 
and a centrally located homeodomain. The N-terminal Zn-finger cluster (NZF) contains 
four Zn-fingers (three CCHH fingers and one CCHC finger), while the other cluster 
(CZF), located in the C-terminal part of the protein, contains three CCHH zinc fingers. 
The homeodomain is POU-like and does not bind DNA, so it might be mainly involved 
in protein-protein interactions (Fig. 4). The mouse homolog zeb1 has a very similar 
structure (Vandewalle et al., 2009). 
 
Fig. 4: Schematic representation of ZEB1 transcription factor. It contains two zinc 
finger clusters, one at each end (NZF and CZF) and a centrally located homeodomain 
(HD). Other domains are the Smad binding domain (SBD) and the CtBP interaction 
domain (CID). ZEB1 acts mainly as transcriptional repressors by high-affinity binding of 
the two zinc finger domains to specific DNA binding sites, called E-boxes (CACCT(G)). 
An alternative role as transcriptional activator, however, cannot be excluded. In the 
ZEB1 protein a transcriptional activation domain and a binding site for the co-activators 
p300 and P/CAF were identified. ZEB1 is posttranslationally modified by SUMOylation 
(SUMO), which affects its repressor activity. Adapted from (Vandewalle et al., 2009). 
 
The Zinc finger domains can bind simultaneously different E-boxes [5’-CACCT(G) 
sequences] on promoter regions of target genes and thereby alter their transcriptional 
activity. The list of ZEB target genes is growing fast but the mechanism of action by ZEB 
proteins remains elusive. The structural complexity of this protein, combining several 
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binding sites for co-repressors with potential posttranslational modifications, points to 
intricate modes of action. CtBP was originally identified as a protein interacting with a 
PLDS sequence in the C-terminal segment of the adenovirus E1A oncoprotein (Schaeper 
et al., 1995). The identification of PXDLS motif in ZEB1 led to the assumption that CtBP 
can act as a co-repressor for this protein. Recently, a CtBP co-repressor core complex 
was identified. This complex contains both ZEB1 and ZEB2, together with histone 
modifying enzymes (histone deacetylases and histone methyltransferases), 
chromodomain-containing proteins, coREST and coREST related proteins, thereby 
combining all essential elements for promoter targeting, transcriptional repression and 
chromatin remodeling (Shi et al., 2003a). Controversially, in overexpression experiments, 
CtBP does not seem to be required for repression of E-cadherin transcription by full-
length ZEB1 (van Grunsven et al., 2003). 
ZEB1 has been shown to repress gene expression in several cell types: in haematopoietic 
cells, it negatively regulates the expression of Interleukin 2, Immunoglobulin-μ-heavy 
chain, CD4, GATA-3 and α4-Integrin (Brabletz et al., 1999; Genetta et al., 1994; 
Gregoire and Romeo, 1999; Postigo and Dean, 1997). In mesenchymal cells, ZEB1 
inhibits p73 gene expression; p73, a new p53-homolog, is an in vivo transcriptional target 
of the muscle regulatory factors MyoD, Myogenin, Myf5 and Myf6. Ectopic expression 
of ZEB1 counteracts MyoD mediated transcriptional activation of p73. ZEB1 plays also a 
role in the transcriptional regulation of p53 family members during keratinocytic 
differentiation (Fontemaggi et al., 2005). 
During skeletal myogenesis, ZEB1 suppresses α7-Integrin expression in myoblasts, by 
displacing MyoD, an activator of α7-Integrin, and competing for p300/CBP, a coactivator 
(Pipaon et al., 2005). In osteoblasts it represses Type I and Type II Collagen expression 
(Murray et al., 2000; Terraz et al., 2001), and it activates the expression of the Ovalbumin 
and Vitamin D3 receptor genes in some cell types, although the molecular mechanism 
behind this activation effect is unknown (Chamberlain and Sanders, 1999; Dillner and 
Sanders, 2002; Lazarova et al., 2001). 
Evidence that ZEB1 is an active repressor has been proposed because a repression 
domain close to the N-terminus is necessary for repression of the δ-crystallin enhancer 
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(Sekido et al., 1997). Postigo et al. (Postigo and Dean, 1999), postulated that ZEB1/δ-
EF1 contains two independent repressor domains, with one domain, close to the C-
terminus, regulating muscle differentiation and specifically blocking the activity of the 
myogenic transcription factor MEF2C (Fig. 4). The other domain, near the N-terminus, is 
postulated to function in lymphocytes to regulate the activity of hematopoietic factors 
such as c-Myb and Ets family members. 
Though most research has focused on the ability of ZEB1 to repress gene expression, its 
ability to activate transcription has also been reported. Regulation of vitamin D3 receptor 
(VDR), a steroid-thyroid receptor determining developmental differentiation processes as 
well as the differentiation status of several malignant cell lines, is at least partly mediated 
by ZEB1. ZEB1 binds to two sites within the VDR promoter in vitro and therefore 
presumably activates transcription of this receptor directly (Lazarova et al., 2001). 
Recruitment of coactivators like p300 or P/CAF and displacement of CtBP may also be 
part of this mechanism. Indeed coexpression analysis of CtBP, p300, ZEB1, VDR and 
CDH1 in a series of colon carcinomas indicates that the expression level of the co-
regulator determines the repressor or activator status of ZEB1 (Pena et al., 2006). 
Recently, functional cooperation between FOXO transcription factors and ZEB1 in B 
lymphocytes has been revealed (Chen et al., 2006). ZEB1 binds to and activates the 
promoters of two FOXO target genes, Ccng2 (cyclin G2) and Rbl2 (retinoblastoma-like 
protein p130/Rb2), both of which are implicated in cell cycle arrest and FOXO-
dependent quiescence in fibroblasts. ZEB1 activates transcription of these two genes and 
strongly synergizes with FOXO proteins. 
The molecular mechanisms underlying the choice between repression and activation by 
ZEB1 are currently unknown, but may include cell type specific differences in post-
translational modification. Both hyperphosphorylated and hypophosphorylated forms of 
ZEB1 are expressed in cell lines. Differential expression of these two forms may 
contribute to cell type specific activities of ZEB1 (Costantino et al., 2002). 
Phosphorylation may also modify the ability of ZEB1 to interact with certain 
corepressors or co-activators, providing an additional mechanism for regulating 
transcriptional activity by ZEB1. 
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In the developing mouse embryo, ZEB1/ δ-EF1 is expressed in the notochord, somites, 
limb, neural crest derivatives and restricted sites of the brain and spinal cord (Darling et 
al., 2003; Takagi et al., 1998). To investigate the in vivo function of ZEB1 during mouse 
development, knock-out mice were generated. Homozygous ZEB1-deficient mice die 
perinatally due to respiratory failure and exhibit multiple skeletal defects including 
craniofacial abnormalities, limb and sternum defects, malformed ribs and hypoplasia of 
intervertebral discs, in addition to severe thymus defects most likely due to inappropriate 
differentiation of T-cells and their inability to populate the thymus (Higashi et al., 1997; 
Takagi et al., 1998). This is in accordance with the previously mentioned role for ZEB1 
as a repressor of collagen type-I and –II genes, indicating that ZEB1 might be a direct 
modifier of chondrogenesis. Although ZEB1 expression was shown in developing neural 
tissues, no distinctive phenotypic change was seen in the central nervous system of the 
ZEB1 deficient mice. 
ZEB1 was shown to bind, although less efficiently, to activated R Smads-1, -2 and -3, 
indicating a role in both BMP and TGFβ signaling (Postigo, 2003). A conserved region 
downstream of the N-terminal zinc finger cluster was recognized as the Smad interacting 
domain (SBD in Fig. 4) (Postigo, 2003; Verschueren et al., 1999). ZEB proteins (ZEB1 
and ZEB2) are crucial regulators of TGFβ/BMP signaling with opposing effects on this 
pathway. Both ZEB proteins bind to Smads, but while ZEB1 synergizes with Smad 
proteins to activate transcription, promote osteoblastic differentiation and induce cell 
growth arrest (Postigo, 2003), the highly related ZEB2 protein has the opposite effect. It 
was found that ZEB2 inhibited activation by TGFβ of the p21, p15 and c-jun promoter 
reporters. These antagonistic effects were reported to result from the differential 
recruitment of transcriptional co activators (p300 and P/CAF) and co-repressors (CtBP) 
to Smads by ZEB1 and ZEB2, respectively (Postigo, 2003). Recently, these data were 
extended with the finding that ZEB1, ZEB2 and SNAI1 are induced in NmuMG cells 
upon treatment with TGFβ. This results in a spectacular EMT with loss of E-cadherin 
expression that is dependent on both ZEB1 or ZEB2 but not on SNAI1 (Shirakihara et al., 
2007). In addition, recent reports indicated that the miR141, miR200 family and miR205 
directly target ZEB1 and ZEB2 resulting in repression of ZEB1 and ZEB2 protein 
expression (Burk et al., 2008; Christoffersen et al., 2007; Gregory et al., 2008; Hurteau et 
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al., 2007; Park et al., 2008). Expression analysis of miRNAs in normal human tissues 
made clear that the miRNAs targeting ZEB family members are particularly abundant in 
epithelial tissues (Liang et al., 2007). Interestingly, these different miRNAs are repressed 
by TGFβ treatment or via overexpression of the tyrosine phosphatase Pez, which results 
in EMT with loss of E-cadherin expression (Gregory et al., 2008). Furthermore, ZEB1 
potently represses transcription of miR141 and miR200c. The EMT activator TGFβ2 is 
also strongly downregulated by these miRNAs, indicating that ZEB1 induces a 
microRNA-mediated feedforward loop (Burk et al., 2008). It was recently shown that 
ZEB1 represses expression of stemness-inhibiting miR‑203 and that candidate targets of 
miR‑200 family members are also stem cell factors, such as Sox2 and Klf4. Moreover, 
miR‑200c, miR‑203 and miR‑183 cooperate to suppress expression of stem cell factors 
in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb 
repressor Bmi1. Thus, ZEB1 links EMT-activation and stemness-maintenance by 
suppressing stemness-inhibiting microRNAs (miRNAs) and thereby is a promoter of 












2.7 Aims of the Thesis 
ZEB1 is increasingly considered important contributor to the process of malignant cancer 
progression. Ectopic expression of ZEB1 was shown to be sufficient to downregulate E-
cadherin and to induce EMT in a breast cancer model by our lab (Eger et al., 2005). 
ZEB1 downregulates E-cadherin transcription, by binding to the conserved E-boxes in 
the minimal E-cadherin promoter. More studies were needed for further characterization 
of ZEB1 as a regulator of epithelial cell plasticity and its role in inducing EMT. To 
analyse EMT-causing pathways in tumourigenesis, transcriptional targets of the E-
cadherin repressor ZEB1 in invasive human cancer cells were identified. This thesis 
focuses on role of ZEB1 in promoting tumour cell dedifferentiation by repressing master 
regulators of epithelial polarity.  
ZEB1 has been shown to associate with the co-repressors CtBP1 and CtBP2, which in 
turn are capable of interacting with histone-deacetylases (HDACs) thus establishing a 
multiprotein complex at the promoter of the E-cadherin gene, which leads to covalent 
modifications of histones and DNA, resulting in promoter specific chromatin 
condensation and repression of transcription.  In the present study, I checked the ZEB1 











3  Materials and Methods 
3.1  siRNA - Mediated Knockdown of ZEB1 and SNAI1 
For the siRNA-mediated knockdown of ZEB1, highly invasive breast cancer cell line 
MDA-MB-231 was used. Cells were plated at 50-60% confluence in antibiotic-free 
RPMI 1640, supplemented with 10% fetal calf serum; (both from Gibco). Transfection of 
cells was carried out using Oligofectamine and Opti-MEM (both from Invitrogen). 
3.1.1 Transfection of Cells 
Transfection conditions were optimized for MDA-MB-231 cells using a fluorescently-
labeled unspecific RNA oligo (Neg. control siRNA, Rhodamine, Qiagen). For a 6cm2 
dish 9 μl of 20 μM siRNA was mixed with 270 μl of Opti-MEM (mix A) and 12µl 
Oligofectamine was combined with 48 μl Opti-MEM  (mix B). Mix A and mix B were 
combined within 5 min of preparation, incubated for 15 min at room temperature and the 
mixture was added drop-wise to the cells pre-washed with and having 1.5 ml Opti-MEM. 
After 24 h the cell culture media was changed. 
The following pre-annealed ZEB1 and SNAI1 specific siRNA oligos and unspecific 
control oligos were used for transfections: 
siRNA ID: Control (Qiagen) 
Sequence (sense): 5’ r(GAAUCUGACUAGUUAAGAG)dTdT- 3’ 
siRNA ID: Custom siRNA: TCF8/ZEB1 (Qiagen) 
Sequence (sense): 5’ r(UGAUCAGCCUCAAUCUGCA)dTdT - 3’ 
siRNA ID #: 115741 (siSNAI1, highly efficient on RNA level) (Ambion) 
Sequence (sense): 5’ CGAGGUGUGACUAACUAUGtt- 3’ 
siRNA ID #: 115742 (siSNAI1, medium efficient on RNA level) (Ambion) 
Sequence (sense): 5’ CCUGUUUCCCGGGCAAUUUtt - 3’ 
siRNA ID #: 107915 (siSNAI1, medium efficient on RNA level) (Ambion) 
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Sequence (sense): 5’ GGUGUGACUAACUAUGCAAtt - 3’ 
Approximately 72 hours post transfection; cells were either processed for RNA and 
Western blot according to standard protocols or used for Chromatin immunoprecipitation.                               
3.1.2 Extraction of Total RNA 
Total RNA was extracted with Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. 
3.1.3 Reverse Transcriptase PCR 
Poly (A)+ mRNAs were isolated and reverse transcribed using the mRNA Isolation Kit 
and the 1st Strand cDNA Synthesis Kit for RT-PCR (both from Roche). cDNAs were 
normalized based on actin expression levels. PCR amplification was performed with 
puReTaq-Ready-To-Go PCR beads (Amersham Pharmacia Biotech) using primers 
specific for E-cadherin, ZEB1, Snail and SIP1. PCR conditions were optimized for each 
primer pair.  
Primer pairs used were: 
Actin-F: 5’ - ATCTGGCACCACACCTTCTAC - 3’ 
Actin-R: 5’ - CAGCCAGGTCCAGACGCAGG - 3’ 
E-Cad-F: 5’ - GAGCCTGAGTCCTGCAGTCC - 3’ 
E-Cad-R: 5’ - TGTATTGCTGCTTGGCCTCA - 3’ 
ZEB1-F: 5’ - TTCAAACCCATAGTGGTTGCT - 3’ 
ZEB1-R: 5’ - TGGGAGATACCAAACCAACTG - 3’ 
Snail-F: 5’ - ACCTTCCAGCAGCCCTACGACC- 3’ 
Snail-R: 5’ - GTGTGGCTTCGGATGTGCATC- 3’ 
SIP1-F: 5’ - CAAGAGGCGCAAACAAGC - 3’ 
SIP1-R: 5’ - GGTTGGCAATACCGTCATCC - 5’ 
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3.2 Chromatin ImmunoPrecipitation (ChIP) 
ChIP analyses were done using the ChIP Assay Kit from Upstate Biotechnology. Cells 
were cross-linked with 1% formaldehyde (Merck) for 10 minutes at room temperature. 
Cross-linking was stopped by adding glycine to a final concentration of 0.1M. Cells were 
harvested in PBS in the presence of Protease inhibitor cocktail (Roche) and resuspended 
in lysis buffer. Samples were sonicated 10 times for 15s in a Sonoplus GM70 (Bandelin, 
Berlin, Germany) at cycle 90% and output 40% to generate DNA fragments of 
approximately 200- to 500-bp lengths. Cell lysates were diluted 1:10 with dilution buffer, 
divided into approx. 900 μL aliquots. Five to Ten micrograms of the appropriate antibody 
were added and the mixture was incubated overnight at 4°C on a rotating wheel. 
The next day, 30 μL ProteinA or ProteinG Sepharose beads (Amersham Pharmacia 
Biotech) were added to each ChIP aliquot and incubated with end over end rotation for 
3 hours at 4°C. Chromatin-antibody-protein-A/protein-G agarose complexes were 
washed once with 1 ml cold low-salt wash buffer, once with high-salt wash buffer, once 
with LiCl immune complex wash buffer, and twice with TE buffer. Chromatin–antibody 
complexes were eluted from the protein-A or G sepharose beads by addition of freshly 
prepared elution buffer (1% SDS, 0.1M NaHCO3 and 10mM dithiothreitol). Antibody-
chromatin complexes were reversed by adding NaCl to 0.2 M final concentration and 
incubation for 16 h at 65°C. Proteinase K digestion was done by Incubating samples with 
Proteinase K for 1 hr at 45°C on a shaking thermomixer. The DNA was extracted with 
phenol–chloroform, precipitated with ethanol in the presence of 6 µg of the glycogen 
(Roche,  Cat. No. 901393) as carrier and dissolved in water. PCR reactions were 
performed with the following primers for Human E-cadherin promoter:  







Table 3-1: Antibodies used for Chromatin ImmunoPrecipitation (ChIP) 






Histone H4 antibody Millipore 07-108 Rabbit polyclonal 5 µl (5 µg) 
applied 
Anti-acetyl-Histone H4 antibody Millipore 06-866 Rabbit polyclonal 10 µl serum 
applied 
Anti-acetyl-Histone H3 antibody Millipore 06-599 Rabbit polyclonal 10 µl (10µg) 
applied 
Anti-dimethyl-Histone H3 (Lys9) 
antibody 
Millipore 07-521 Rabbit polyclonal 5 µl (5µg) 
applied 
Anti-dimethyl-Histone H3 (Lys27) 
antibody 
Millipore     
 
3.3 Luciferase and β-Galactosidase Reporter Assay 
 
Beta-Galactosidase Lysis buffer: 
250 mM Tris pH 7.5 
0.5 % Triton-X 
100x Mg-Solution (Sol. 2): 
0.1 M MgCl2 
4.5 M beta-mercaptoethanol 
 
ONPG: 
4 mg/ml in 0.1M Sodium phosphate, pH 
7.5 
0.1M Sodium phosphate pH 7.5 (Sol. 3) 
41 ml 0.2M Na2HPO4 
9 ml 0.2M NaH2PO4 
50 ml H2O 
 
Cells were seeded the day before transfections on a 12 well plate, transfected, using the 
Lipofectamin-2000 reagent, with 25 ng of the β-Galactosidase expression vector, 50 ng of the 
respective construct to be tested and with either 75 ng of the control vector or with 1.75 μg 
pcDNA-TCF8, the TCF8 expression vector. 
The transfections were all done in triplets. 
The following day, cells were lysed in 200 μl beta-Galactosidase-Lysis buffer, scraped and 
transferred in an eppendorf tube. After incubation on ice and centrifugation at 4°C, supernatant 
was transferred in a new tube. 
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For the β-Galactosidase assay 50 μl cell extracts were combined with 4 μl 100x Mg- Solution, 88 
μl ONPG and 268 μl 0.1 M Sodium Phosphate pH 7.5. The negative control contained 760 μl 
H2O and 50 μl beta-Galactosidase-Lysis buffer. β-Galactosidase activity was measured at 420 
nm. Luciferase was measured in presence of 350 μl Assay Buffer and the supplied Injection 
Buffer. 
Table 3-2: Amounts for Assay Buffer and Injection Buffer. 





        





2.5ml 3ml 4ml 5ml 5ml 7.5ml 10ml 12.5ml 
 
1.0M MgSO4 150μl 180μl 240μ 300μl 360μl 450μl 600μl 750μl 
 




10ml 12ml 16ml 20ml 24ml 30ml 40ml 50ml 
 









2ml 2.4ml 3.2ml 4ml 4.8ml 6ml 8ml 10ml 
 
 
3.4 Cell Migration and Invasion Assays 
3.4.1 Transpore migration assay 
Three days after ZEB1 and Snail1-siRNA treatment, 50000 cells were transferred to 24-well 
Transwell filter inserts (Corning, NY, USA) (8 mm, Costar). After 24h, cells were fixed in 2.5% 
formaldehyde and cells on the lower side of membrane were stained with Hoechst 33258 




3.4.2 Invasion Assay 
BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, MA) were used to determine 
cell invasion. The BD BioCoat Matrigel Invasion Chamber consists of a Companion Plate with 
Cell Culture Inserts containing an 8 micron pore size PET membrane with a thin layer of 
matrigel basement membrane matrix. The matrigel matrix serves as a reconstituted basement 
membrane in vitro. This layer occludes the pores of the membrane, thereby blocking non-
invasive cells from migrating through the membrane. In contrast, invasive cells are able to detach 
themselves from and invade through the matrigel matrix and the 8 micron membrane pores. 24-
well tissue culture plate inserts coated with Matrigel were re-hydrated for 2 h in 37˚C RPMI in a 
humidified tissue culture incubator at 37˚C, 5% CO2 atmosphere. Calculated numbers of cells 
for different experiment as shown in results section were plated on the insert in 0.5 ml of RPMI 
while 0.75 ml of RPMI + 10% FCS was added into the lower chamber. After incubation for 24 
hours, non-invading cells were removed from the upper side of the membrane by scrubbing with 
a cotton swab. Cells at the lower side of membrane were fixed and stained with100% methanol 
and 1% Toluidine blue, respectively. Invading cells were photographed with  axiovision 
microsope at 100X magnification and cells were counted in several fields of triplicate 
membranes. 
3.4.2 Electric cell–substrate impedance sensing (ECIS) 
To determine whether si-ZEB1 or si-SNAI1 affect transcellular resistance across endothelial 
cells, ECIS was used across HUVEC endothelial cell monolayer. ECIS electrode arrays (8W10E) 
were obtained from Applied BioPhysics. Each array slide consists of eight individually 
addressable wells with surfaces treated for cell culture. HUVEC (Human Umbilical Vein 
Endothelial Cells) were grown as a confluent layer covering each electrode. MDA-MB-231 
control, si-ZEB1, si-SNAI1 and si-ZEB1 & si-SNAI1 were stained with cell tracker and 10,000 
cells from each were seeded per chamber. Resistance was monitored for up to 12 hours. Cells 
were harvested from bottom and fluorescence was measured with PARADIGM™ Microplate 




3.5 Generation of Stable Clones  
MDA-MB-231 stably expressing E-Cadherin was obtained by transfection with Lipofectamine 
2000 (Invitrogen, Cat. No. 11668-027), while Snail expressing MCF7 breast cancer cell line was 
transfected using Magnet Assisted Transfection (MATra A reagent from IBA, Cat. No. 7-2001-
100) 
3.5.1 Stable Expression of E-Cadherin in MDA-MB-321 
For stable Transfection of E-Cadherin, MDA-MB-321 cells were transfected using 
Lipofectamine 2000 and plasmid vector encoding C-terminally EGFP-tagged E-Cadherin 
(pAS17), under the control of a CMV promoter. For a 6cm2 dish 8 μg of DNA was mixed with 
250 μl of Opti-MEM (mix A) and 10µl Oligofectamine was combined gently with 250 μl Opti-
MEM (mix B). Mix A and mix B were combined after 5 min of preparation, incubated for 20 
min at room temperature and the mixture was added drop-wise to the cells pre-washed with and 
having 2 ml of antibiotic free RPMI. Cells were incubated for 2-3 hours at 37°C, then a medium-
change was performed. Stable clones were selected after 3-4 days using G-418 (Geneticin®, 
Invitrogen) at a concentration of 1000 ug / ml for selection and 400 ug / ml for maintenance. 
3.5.2 Stable Expression of SNAI1 in MCF7 Cells 
For stable Transfection of SNAI1, MCF7 cells were transfected using the MATra A reagent and 
a plasmid vector encoding either N-terminally Flag-tagged wild type snail (Snail-WT) or N-
terminally Flag-tagged mutated Snail (Snail-6SA), under the control of a CMV promoter. These 
vectors were obtained from Mien-Chie Hung (Zhou et al., 2004). For a 6cm2 dish 6.6µg DNA 
was diluted in 400 µl serum-free and supplement-free medium, added to 6.6 µl of MATra 
Reagent, mixed thoroughly and incubated at ambient temperature for 20 minutes. This DNA-
Bead-mixture was then added to the cells, pre-washed with and containing 4ml of antibiotic free 
DMEM. The plates were placed immediately on the 96 Magnet Plate for 15 minutes in the 
incubator at 37°C. Medium exchange was performed after 24 hours and Stable clones were 
selected after 3-4 days using G-418 (Geneticin®, Invitrogen) at a concentration of 1000 ug / ml 
for selection and 400 ug / ml for maintenance. 
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3.6 Immunological Assays 
3.6.1 Immunofluorescence  
The cells were washed with Hanks’ Balanced Salt Solution (HBSS) temperated at 37°C, fixed 
with 2.5 % formaldehyde in HBSS, washed with HBSS and PBS. The cell membranes were 
permeated with 0.2 % Triton-X-100 in PBS and quenched with 50 mM NH4Cl/ 0.1 % Glycin in 
PBS. After scratching out an appropriate window and lining with Dako pen, the cells were 
incubated with the first antibodies and after washing with PBS incubated with the labeled 
secondary antibodies. For the nuclear staining the cells were incubated with Hoechst diluted 1:10 
000, finally the plates were mounted with Mowiol and coverslips. 
3.6.2 Western Blot Analysis 
The cells were grown until confluence, washed, scraped in Lysis buffer with Dnase and Rnase (5 
mM Hepes/HCl pH 7.0; 0.5 mM MgCl2; 0.1 mM EGTA; 10 mM NaCl; 0.5 % Triton-X-100; 100 
nM DTT; 0.5 mg Dnase; 0.2 ng Rnase; 5 % Proteaseinhibitormix) and incubated 10 minutes at 
RT. After adding 3x Sample buffer they were boiled at 95°C for 10 minutes and stored at -20°C. 
Samples were heated to 95°C for 5 minutes before electrophoretic separation of proteins by SDS 
PAGE. Lysates were loaded on a 8-12.5 % SDS-PAGE gel, transferred on a Nitrocellulose 
membrane, blocked in 2% Bovine Serum Albumin in PBST (0.005 % Tween in PBS) at RT and 
incubated at RT with the primary antibody, diluted in 2 % BSA/PBST and 0.2 % Sodium azide; 
after incubation with the secondary antibody conjugated with Horse Raddish Peroxidase, the 
membrane was developed with Pierce Supersignal West Pico Chemiluminescent Substrate. 
3.6.3 Immunohistochemical Staining of Paraffin Sections 
The paraffin sections were hydrated in a washing series of Xylene, Isopropanol, 96 % Ethanol, 
80 % Ethanol, 70 % Ethanol, 60 % Ethanol and finally ddH2O and boiled in Citrate working 
solution (1.8 ml of 0.1M citric acid monohydrate (C6H8O. H2O) solution + 8.2 ml 0.1 M 
trisodium citrate dihydrate (C6H5Na3O7. 2H2O) solution, pH 6.0 filled up to 100 ml H2O; pH 
6.0). The endogenous peroxidases were inactivated by incubating the sections in 2 % H2O2. The 
blocking step is performed in M.O.M Protein diluent (600 μl Protein Concentrate stock solution 
in 7.5 ml PBS). Primary antibodies were diluted in M.O.M Protein diluent. After washing with 
PBS, the biotinylated secondary antibodies were applied. The Vectastain Elite ABC reagent (2.5 
ml PBS, 1drop of reagent A and B) was mixed 30 minutes before incubation of other 30 minutes, 
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and then developed with DAB or Vector VIP Peroxidase Substrate Kit from Vector Laboratories. 
The sections were counterstained with Haematoxylin, dehydrated by traversing the washing 
series backwards and mounted with Entellan Neu and cover slips. 
Vectastain ABC Kit Peroxidase Elite Cat. No. PK6101 
M.O.M Kit Peroxidase Cat. No. PK2200 for detecting mouse antibodies on mouse tissues 
Horse biotinylated 2nd Ab α-goat 
DAB Kit Cat. No. SK 4100 
Vector VIP Kit Cat. No. SK 4600 
Source: Vector Laboratories 
3.6.4 Immunofluorescence of Paraffin Sections 
The paraffin sections were hydrated, boiled in Citrate working solution as above and treated with 
0.1% Triton-X-100 for 5 minutes. After washing, the blocking step is performed again as above. 
Primary antibodies were diluted in M.O.M Protein diluent. After washing with PBS, the labelled 
secondary antibodies were applied. Then the section were as usual counterstained with Hoechst 
diluted 1:100, washed, dehydrated as for the Immunohistochemistry and mounted in Mowiol. 
Table 3-3: Antibodies used for Westren Blot (WB), immunofluorescence microscopy (IF) and 
immunohistochemistry (IHC) of tissues or cells. 






















Mouse monoclonal WB 1:2500 
IF 1:100 
 
ZO-1 BD Biosciences Mouse monoclonal IF 1:100 
HUGL2 Santa Cruz Biotechnology Rabbit polyclonal IF 1:50 
 
PKP3 (23E3/4) Zymed Laboratories Mouse monoclonal WB 1:2000 
IF 1:50 
Crumbs3 * Rabbit polyclonal IF 1:50 
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PATJ Santa Cruz Biotechnology Goat polyclonal IF 1:50 























Desmoplakin 1&2 Progen Biotechnik Mouse monoclonal IF 1:25 
Actin Sigma Rabbit polyclonal  
Secondary Abs coupled 
to Alexa Fluor 488 
Molecular Probes  IF 1:300 
Secondary Abs coupled 
to Texas Red or 
Peroxidase 
Jackson Laboratories  IF 1:300 
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ABSTRACT 
Epithelial to mesenchymal transition (EMT) is a vital process during early development that is 
also implicated in pathological malignancies in adults. E-Cadherin down-regulation and 
reorganization is a well known marker of EMT and metastasis. We show here that ZEB1 over-
expression down-regulates and relocalizes E-Cadherin in MCF7 and T47D cells, moreover, 
ZEB1 over-expression results in reduced proliferation rate of these cells. We further demonstrate 
the invasion potential of highly invasive breast cancer cell line MDA-MB-231, to be under the 
control of ZEB1. Most importantly, we show that ZEB1 mediated downregulation of E-cadherin 
involves chromatin modifications. Markers of transcriptionally active chromatin Acetylated H3 
and Acetylated H4 were increased upon ZEB1 knock down in MDA-MB-231 cells, while 






During the process of EMT, sessile epithelial cells organized into a collective unit lose 
characteristic cell junctional proteins and cytoskeletal elements, while gaining motility, 
mesenchymal cadherins and vimentin-rich intermediate filaments. This process marks the onset 
of cancer cell migration, invasion and metastatic dissemination(Grunert et al., 2003; Thiery and 
Sleeman, 2006; Yilmaz and Christofori, 2009). E-cadherin is important for the maintenance of 
tissue architecture. Thus, loss of E-cadherin function has been found to be widespread in 
sporadically arising epithelial tumors and is thought to be an important step in the development 
of most, if not all, epithelial-derived tumor types and loss of E-cadherin function in tumors 
results in the rapid progression from a benign adenoma to an invasive, metastatic carcinoma. 
These observations have prompted the designation of E-cadherin as an invasion- or metastasis-
suppressor (Baum et al., 2008; Guilford, 1999). Mutation of the coding sequence accounts for 
only a minority of cases of E-cadherin dysfunction in cancer (Berx et al., 1995; Guilford et al., 
1998; Risinger et al., 1994). More commonly, Cadherin expression is reduced by transcriptional 
silencing, notably through a variety of transcription factors that target the E-cadherin promoter 
(Thiery, 2002).  These include transcriptional repressors of the Snail/slug family that are 
overexpressed in advanced carcinomas, reviewed in (Moreno-Bueno et al., 2008); and the 
transcriptional repressors ZEB1/δEF1 and ZEB2/SIP1, reviewed in (Vandewalle et al., 2009). 
However, transcriptional repression is insufficient to account for the extensive E-cadherin 
suppression in cancers, epigenetic silencing of the gene by histone modifications and DNA 
hypermethylation also plays a crucial role (Jones and Baylin, 2002; Strathdee, 2002). 
ZEB1 (also known as dEF1, Nil-2-a, Tcf8, Bzp, Areb6, Meb1, Zfhx1a and Zfhep) has been 
identified as a nuclear factor that specifically binds to and represses the lens-specific d1- 
crystallin enhancer in chicken (Funahashi et al., 1993). This zincfinger- homeodomain protein is 
complex transcription factor that has several functional domains, featured by two separate arrays 
of C2H2-type Zn-finger domains and a centrally located homeodomain. ZEB1 can repress 
transcription by directly binding to 5’-CACCT sequences located in various gene promoters. The 
list of ZEB target genes is growing fast but the mechanism of action remains elusive. The 
structural complexity of this protein, combining several binding sites for co-repressors with 
potential posttranslational modifications, points to intricate modes of action (Vandewalle et al., 
35 
 
2009). Recently, a CtBP co-repressor core complex was identified. This complex contains both 
ZEB1/δEF1 and ZEB2/SIP1, together with histone modifying enzymes (histone deacetylases and 
histone methyltransferases), chromodomain-containing proteins, coREST and coREST related 
proteins, thereby combining all essential elements for promoter targeting, transcriptional 
repression and chromatin remodeling (Shi et al., 2003b). In the present study we demonstrate, on 
chromatin immunoprecipitation level, that histone modifications on E-cadherin promoter are 
under the control of transcription factor ZEB1. 
RESULTS 
ZEB1 over-expression down-regulates and relocalizes E-Cadherin in Human Epithelial 
cells 
Exogenous  expression of ZEB1 or its mouse homolog δEF1 is shown to downregulate and 
relocalize E-Cadherin in EpFosER murine mammary tumour model (Eger et al., 2005). In order 
to verify the same phenomenon in human tumour models, whether ZEB1 represents a major 
regulator of epithelial plasticity in human cancer progression, invasion and metastasis, we used two 
commercially available epithelial cell lines, T47D Tet-on and MCF7, which are derived from human 
breast cancer patients. Doxycycline inducible ZEB1 and GFP expressing cell clones were generated 
for T47D Tet-on cells, while ZEB1 expressing stable clones and mock transfected control were 
generated for MCF7 cells. In T47D Tet-on cells, upon treatment with Doxycycline, several cell 
clusters displayed a strong accumulation of ZEB1 in the nucleus. Concomitantly, E-cadherin 
localization was changed dramatically. The protein mostly disappeared from the lateral plasma 
membrane and accumulated in cytoplasmic aggregates and vesicle-like structures of unknown 
origin. Thus, de novo expression of ZEB1 affected epithelial differentiation by inducing 
reduction and internalization of E-cadherin and thereby preventing proper intercellular adhesion 
(Figure 1a). In few days the cells lost their ZEB1 expression because of proliferation reduction of the 
transfected cells. Concomitantly, E-cadherin often relocalized back to the plasma membrane, albeit 
the cells did not regain a fully developed epithelial and polarized phenotype (Figure 1a and 2a). 
Similarly in MCF7 cells, ZEB1 expressing cells did not exhibit a significant E-cadherin specific 
staining at the cell periphery, a weak vesicular staining of the protein could only be detected at 
perinuclear regions, at immunoflourescence level (Figure 1b). It’s interesting to note that E-
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cadherin in T47D-ZEB1 was primarily detected in vesicular or rod-like aggregates highly 
 
Fig 1. Exogenous expression of ZEB1 results in downregulation and relocalization of E-cadherin in 
epithelial cells. (A) Un-induced and 3 days doxycycline treated T47D Tet-on cells Expressing ZEB1. E-
cadherin is relocalized in the cytoplasm and accumulates in vesicular and rod like structures upon 3 days 
induction with Doxycycline (B) Mock transfected epithelial-like human breast cancer cells MCF7-Control 
and ZEB1 expressing MCF7 cells (MCF7-ZEB1) were fixed in formaldehyde and processed for 
immunoflourescence using antibodies against ZEB1 and E-Cadherin. Confocal images of horizontal 
optical sections are shown. (C) Localization of E-cadherin in 3 days Doxycycline treated T47D-ZEB1 and 
MDA-MB-231 cells. The cytoplasmic rod-like structures of E-cadherin in T47D-ZEB1 clones (white 
arrows) are comparable to the expression and localization of E-cadherin in highly invasive epithelial 
breast cancer cell line MDA-MB-231 (yellow arrows). 
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reminiscent of E-cadherin positive structures in invasive breast cancer cell line MDA-MB-231, 
which expresses extremely low levels of E-cadherin and high levels of ZEB1 (Figure 1c).  
After 7 days of Doxycycline treatment, prominent ZEB1 aggregates appeared within the 
cytoplasm, primarily in the vicinity of the nuclear membrane or at the periphery of the cells at 
the plasma membrane (Figure 2a). To characterize the cytoplasmic aggregates of E-cadherin and 
ZEB1 in more detail, 4 days Doxycycline-treated individual cells were optically sectioned at 
higher magnifications. As shown in Figure 2b, most cytoplasmic aggregates of ZEB1 were found 
at the cellular periphery either at membrane ruffles and membrane extensions or at the cell-
substrate interface. One major accumulation of ZEB1 was also detected on top of the nuclei 
directly overlying the nuclear membrane. The molecular mechanisms that interfere with the 
nuclear localization of ZEB1 and cause its cytoplasmic aggregation and, most likely also affect 
its intracellular stability are completely elusive at present. 
ZEB1 expression results in reduced proliferation rate 
The T47D Tet-on cells stably transfected with ZEB1 proliferated very slowly compared to 
parental or EGFP expressing cell clones, even in the absence of Doxycycline. To directly test the 
effect of ZEB1 on cell proliferation, the cell numbers of parental, mock and ZEB1 expressing 
cells upon Doxycycline treatment was determined for up to six days. Parental and mock 
transfected T47D Tet -on cells did not show any response to Doxycycline, hence the anti-
proliferative effect could not be due to the tetracycline derivative (Figure 3a). On the other hand 
the number of clone-2 and clone-4 cells was strongly reduced upon expression of ZEB1 (Figure 
3b). Moreover, the cells had severe difficulties to attach to the plastic of the Petri dish after 
subcultivation. To distinguish between reduced proliferation and increased apoptosis, TUNEL 
assay was performed to detect and quantify apoptotic cells. But neither clone-2 nor clone-4 cells 
exhibited increased apoptosis rates upon treatment with Doxycycline (Figure 3c). To gain some 
insight into the molecular mechanism for reduced proliferation upon ZEB1 expression, we tested 
the transcription of cell-cycle regulatory genes, Cyclin D1, Cyclin G2, pRbl2/p130, c-Myc, 
p14ARF, p16ink4a, p16ink4a-dct, p21cip1-ct, p27kip1-ct, p53-ct, p73-ct, pcna-ct, tp73I-p63-ct 
and Ki67 (Descovich, 2006). Only mRNA level of the proliferation marker Ki67 was 
significantly reduced in both clones upon ZEB1 induction (Figure 3d). Similar reduction in 





Fig 2. Localization of ZEB1 and E-Cadherin upon ectopic expression of ZEB1. (A) Expression of ZEB1 
and E-cadherin in untreated or 7 days Doxycycline treated T47D-ZEB1 clone2 cells. Note the 
cytoplasmic aggregates of ZEB1 in long term Doxycycline treated cells. E-cadherin partially relocalized 
back to the plasma membrane (yellow arrows). (B) Horizontal and vertical sections of 4 days 
Doxycycline treated T47D-ZEB1 clone2 cells, showing the aggregation of ZEB1 and the abnormal 
network-like structures of E-cadherin in the cytoplasm. E-cadherin positive structures formed an 
extensive intracellular network and ZEB1 is found almost entirely in aggregates. One of these aggregates 
was always found on top of the nucleus (vertical section). 
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Invasion potential in highly invasive MDA-MB-231 cells is under the control of ZEB1 
Invasiveness is the hallmark of aggressive cancers and is an important feature of EMT. We 
performed matrigel invasion assays, trans-endothelial assays and ECIS to determine whether 
knock down of ZEB1 also affects cell invasion in vitro. ZEB1 knock down was already shown to 
reduce migration potential of MDA-MB-231 upto 80% of untreated cells (Aigner et al., 2007a). 
Fig 4a shows the MDA-MB-231 cells expressing E-Cadherin ectopically which had no effect on 
cell adhesion. MDA-MB-231 cells treated with siRNA specific to ZEB1, SNAI1 and ZEB1 & 
SNAI1 both were plated onto Matrigel Invasion Chambers 3 days after siRNA and were 
analysed for invasion after 24 hours. 50,000 cells  were plated in each case to see the cell-cell 
adhesion effect. The invasion potential significantly decreased upon siZEB1; siSAI1 had no 
significant effect while ectopic expression of E-Cadherin showed almost no difference to the 
control (Figure 4b). siZEB1 resulted in clear decrease in invasion potential even in cell adhesion 
independent manner when 5,000 and 10,000 cells were seeded (Figure 4c). Trans-endothelial 
invasion using monolayer of HUVEC cells was also impaired upon siZEB1, while siSNAI1 and 
Ectopic E-Cadherin expression were not sufficient to decrease the invasion potential of MDA-
MB-231 cells (Figure 4d). ECIS of MDA-MB-231 siZEB1 alone and siZEB1 & siSNAI1 in 
combination showed higher impedance values compared to control and siSNAI1 alone. These 
data indicate that control MDA-MB-231 cells are more invasive, thus they invade through the 
monolayer of HUVEC cells and thereby reduce the impedance value, while siZEB1 renders them 
less invasive, hence impedance stays higher. siSNAI1 treated cells had no effect on impedance 
and behaved like control cells (Figure 4e). These data indicate that ZEB1 is responsible for the 
migration and invasion potential of MDA-MB-231 cells. 
ZEB1 mediated E-Cadherin repression involves epigenetic modifications 
As already established, ZEB1 physically associates with the E-cadherin proximal promoter and 
functions as a direct transcriptional repressor of E-cadherin (Eger et al., 2005), we wanted to 
check what molecular machinery is used to bring about this repression. To test whether epigenetic 
modifications could be involved in this process, we used DNA methylation inhibitor 5-Aza-2'-
Deoxycytidine and Histone deacetylase inhibitor Trichostatin A on MDA-MB-231 cells. Slight 
increase in E-Cadherin protein level was observed upon Azacytidine and TSA treatments in 
parental MDA-MB-231 cells (Figure 5a). Next, we used the cells with ZEB1 knock down. ZEB1 
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knock down itself derepresses E-Cadherin to a certain extent, Azacytidine and TSA treatments 
 
 
Fig 3. ZEB1 expression interferes with cell proliferation. (A) Proliferation of parental T47D 
Tet on cells upon treatment with 1 μg/ml Doxycycline. Cells show no response to the 
antibiotic concerning their proliferation. (B)  Phase-contrast images of T47D-ZEB1 clone2 
cells treated with Doxycycline. Note the strong reduction in cell number following induction 
of ZEB1 expression in both phase contrast image and the proliferation curve. (C)   TUNEL 
assay to differentiate reduced proliferation and increased apoptosis. Both T47D-ZEB1 
clone2 and T47D-ZEB1 clone4 cells show no increased apoptosis upon treatment with 
Doxycycline. (D) Semi quantitative Reverse Transcriptase-PCR showing the mRNA level of 
Ki67 and Actin in T47D-ZEB1 clone2 and T47D-ZEB1 clone4 cells. Note that upon ZEB 
induction, the mRNA level of Ki67 was reduced. (E) Phase constrast image and proliferation 
curve of parental MCF7 and MCF7-ZEB1. There is strong reduction in cell number in 
addition to loss of cell-cell contacts upon expression of ZEB1. 
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resulted in further increase in E-Cadherin expression levels. The cells also became 
morphologically more flattened, stretched out and appeared to form contacts to the neighboring 
cells (Figure 5b). These findings gave a hint for the involvement of epigenetic modifications in E-
Cadherin repression. So, we performed chromatin immunoprecipitation of MDA-MB-231 cells 
with transient as well as stable knock down of ZEB1 using antibodies against markers of 
chromatin modifications, and amplified human E-Cadherin promoter for the region containing 
maximum number of E boxes as depicted in Figure 5c. Increased H3 and H4 acetylation upon 
both transient and stable ZEB1 knock down indicates transcriptionally active chromatin, while 
ZEB1 knock down erases the repressive marks like H3K9me2 and H3K27me2 on E-cadherin 
promotor. Thus, these data provide evidence that ZEB1 represses E-Cadherin expression via 
chromatin modifications. 
DISCUSSION 
ZEB1 negatively regulates E-Cadherin expression and the proliferation rate 
E-cadherin is located in the adherens junctions, in epithelial cells, where it acts as a major cell-
cell adhesion molecule responsible for distinct epithelial cell polarity and strong intercellular 
interactions. Ecadherin downregulation is regarded as a central event in tumor progression and 
metastasis, as reduction of cell adhesion facilitates ability of tumour cells to migrate individually 
and invade. Despite several proposed genetic and epigenetic mechanisms, loss of E-cadherin is 
often attributed to transcriptional dysregulation. During the past few years, several transcription 
factors were identified as repressors of E-cadherin transcription. Among them, ZEB1 is 
increasingly considered important contributor to the process of malignant cancer progression. In 
present study, ZEB1 expression dramatically changed the intracellular localization of E-cadherin 
in epithelial breast cancer cell lines MCF7 and T47D. E-cadherin was exclusively distributed 
over the entire lateral membrane domain in parental cells. After two to three days of ZEB1 
expression, E-cadherin disappeared from the membrane and was mostly located in vesicular and 
rodlike structures within the cytoplasm. Simultaneously, these cells exhibited strongly reduced 
intercellular adhesion. Similar cytoplasmic structures of E-cadherin have been detected in 
fibroblastoid MDA-MB-231 cells, which express high amounts of endogenous ZEB1. From 
these observations and from previous ZEB1 knock-down experiments(Aigner et al., 2007a; Eger 
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Fig 4. ZEB1 depletion results in decreased invasion potential of MDA-MB-231 cells. (A) 
Immunoflourescence image of MDA-MB-231 cells stably expressing ectopic E-cadherin stained with E-
cadherin antibody. (B) BioCoat Matrigel Invasion Assay of parental MDA-MB-231 (control), siZEB1, 
siSNAI1, both siZEB1 & siSNAI1 and ectopically E-Cadherin expressing MDA-MB-231 cells. 50,000 
cells were seeded for each cell type 3days post-siRNA treatment. Invading cells were quantified after 24 
hours.  (C) Matrigel Invasion assay without cell-cell adhesion. 5000 and 10,000 cells were seeded on 
filters for each cell type in two different experiments shown here. (D) Trans-endothelial invasion assay of 
parental MDA-MB-231 (control), siZEB1, siSNAI1, both siZEB1 & siSNAI1 and ectopically E-Cadherin 
expressing MDA-MB-231 cells. 50,000 cells were seeded for each cell type. Invasion through monolayer 
43 
 
of HUVEC endothelial cells was quantified after 24 hours. (E) ECIS was performed by seeding 10,000 
cells of MDA-MB-231 control, siZEB1, siSNAI1, both siZEB1 & siSNAI1 on confluent monolayer of 
HUVEC cells grown on top of gold electrode of ECIS and impedance was monitored for 180 minutes. 
Normalization curves show that siZEB1and both siZEB1 & siSNAI1 treated MDA-MB-231 cells had 
higher impedance value, while siSNAI1 treated cells had impedance value comparable to that of  control. 
these breast cancer cells and  re-localization of E-cadherin back to the plasma membrane 
correlates with the loss of ZEB1. 
The findings that ZEB1 can strongly reduce the proliferation rate of cancer cells is in line with 
models which consider cancer cell invasion and proliferation as mutually exclusive 
events(Brabletz et al., 2005a; Brabletz et al., 2005b). It has been speculated that the profound 
morphological changes during EMT, such as those observed during embryonic gastrulation or 
during tumor cell invasion might be incompatible with high proliferation rates (Foe, 1989; Jung 
et al., 2001). Interestingly, also the overexpression of SNAI1 can attenuate cell cycle 
progression. Moreover, SNAI1 can confer resistance to cell death induced by the withdrawal of 
survival factors or by pro-apoptotic signals (Vega et al., 2004). 
ZEB1 as a regulator of invasion potential  
It was recently shown for the dedifferentiated breast cancer cell line MDA-MB-231 in which 
RNAi-mediated knock-down of ZEB1 led to the upregulation of a set of cell junctional genes as 
well as cell polarity genes (Aigner et al., 2007a; Aigner et al., 2007b). These data suggest that 
ZEB1 can transcriptionally reprogram the epithelial cell signature towards a more mesenchymal 
type. We used the same highly invasive breast cancer cell line MDA-MB-231 in the present 
study and monitored their invasion potential with siRNA mediated knock down of ZEB1 and 
SNAI1 alone or in combination, in various sophisticated ways. All methods used, gave us similar 
outcome, i.e.  siRNA ZEB1 alone reduced the invasion potential of MDA-MB-231 cells quite 
efficiently. It is interesting to note that siRNA SNAI1 alone was only sufficient to bring a 
smaller change to the invasive potential and the result of combined siRNA ZEB1 and SNAI1 
was similar to siRNA ZEB1 alone. So, from this finding it is clear that ZEB1 alone is sufficient 
for the control of invasiveness of MDA-MB-231 cells. There are some studies emphasizing role 
of SNAI1 in migration and invasion(Fabre-Guillevin et al., 2008; Peinado et al., 2007). The 
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second thing that we checked in these experiments was invasion potential of ectopically E-
 
 
Fig 5. Epigenetic modifications are involved in ZEB1 mediated regulation of E-cadherin in MDA-MB-
231. (A) Immunoblot and phase contrast images of MDA-MB-231 cells treated with DNA 
methyltransferase inhibitor Azacytidine or HDAC inhibitor Trichostatin A for 3 days. E-Cadherin 
expression is slightly increased. (B) Immunoblat and phase contrast images of MDA-MB-231 cell with 
transient knock down of ZEB1, and after treatment with Azacytidine or Trichostatin A for 3 days. Note 
that E-cadherin expression level and cell-cell contacts have increased evidently. (C) Scheme of the human 
E-Cadherin promoter. Relative positions of E-boxes are depicted as black bars along the first 1 kbp of the 
human E-Cadherin promoter. (D)  MDA-MB-231 cells treated with ZEB1-specific (si-ZEB1) or unspecific 
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scrambled (si-Control) si-RNAs for three days were subjected to chromatin immunoprecipitation using 
antibodies against Acetylated Histone 3 (Ac. H3), Acetylated Histone 4 (Ac. H4), Dimethylated Histone3 
Lysine9 (H3K9me2) and Dimethylated Histone3 Lysine27 (H3K27me2). MDA-MB-231 cell with stable 
knock down of ZEB1 (MDA-shZEB1) and control cell expressing only GFP (MDA-shGFP) were also 
subject to ChIP using same antibodies.  Amplified -181 to +62 human E-cadherin proximal regulatory 
promoter region is shown.  
Cadherin expressing MDA-MB-231 cells. Ectopic expression of E-Cadherin was not sufficient to 
induce epithelial genes and barely affected the motility of MDA-MB-231 cells (Aigner et al., 
2007b). Similarly, ectopically expressed E-Cadherin could not block the invasiveness of MDA-
MB-231 cells. Hence we found that ZEB1 is the key factor controlling the invasive properties in 
MDA-MB-231 cells. These findings are in line with immunohistochemical detection of ZEB1 at 
the tumor-host interface in colorectal cancer specimens, accompanied by nuclear β-catenin and 
reduced cytokeratin, strongly indicating dedifferentiation and tumor cell invasion (Aigner et al., 
2007b). Furthermore, ZEB1 is found to be the main modulator of the basement membrane (BM) 
components encoded by genes LAMA3, COL4A2 and LAMC2, and it generates a local, 
transient loss of the BM at the invasive front (Spaderna et al., 2006). ZEB1 therefore seems to be 
a major constituent allowing tumor cell dissemination at these invasive fronts.  
Involvement of chromatin modifications through ZEB1 induce E-Cadherin repression 
During recent years, a series of experimental studies have established a direct role for ZEB1 in 
the repression of E-cadherin (Eger et al., 2005). However, in addition to direct inhibition of E-
cadherin transcription via binding to the E-boxes (CACCTG) present in the E-cadherin promoter, 
the transcriptional suppressive function of ZEB1 may be linked to the recruitment of histone 
deacetylases to gene promoters (Ohira et al., 2003; Yang et al., 2009; Yang et al., 2007). ZEB1 
has been shown to associate with the co-repressors CtBP1 and CtBP2 (Furusawa et al., 1999; 
Grooteclaes and Frisch, 2000; Postigo and Dean, 1999; Zhao et al., 2009), which in turn are 
capable of interacting with histone-deacetylases (HDACs) (Chinnadurai, 2002; Sundqvist et al., 
1998). In this way a specific multiprotein complex is established at the promoter of the E-
cadherin gene, which leads to covalent modifications of histones and DNA, resulting in promoter 
specific chromatin condensation and repression of transcription. In addition, our lab investigated 
interaction partners of ZEB1 and found JMJD2A which also is known to interact with Class I 
HDAC’s (our unpublished data).  In the present study we were able to show the epigenetic 
46 
 
modifications on E-Cadherin promoter, dependent on ZEB1 transcription factor. siRNA 
mediated ZEB1 knock down in MDA-MB-231 cells resulted in loss of suppression and thus 
actively transcribed E-Cadherin, as indicated by loss of repressive marks H3K9me2 and 
H3K27me2 and simultaneous acquisition of Acetylated H3 and H4, the markers of actively 
transcribed genes.  
METHODS 
Cell culture 
MCF7, T47D Tet on and MDA-MB-231 cell lines were cultivated as reported previously (Aigner 
et al., 2007a). 
DNA methylase inhibitor and Histone deacetylase inhibitor treatments 
DNA methylase inhibitor 5-Aza-2'-Deoxycytidine was purchased from Sigma-Aldrich Inc. (St 
Louis, USA). Azacytidine solution was always prepared fresh in PBS at a concentration of 100 
µM, sterile filtered and used at a final concentration of 1µM. Cells were allowed to grow for 48 
hours in the presence of Azacytidine. Then, the cells were grown in Azacytidine free medium for 
another 24 hours before proceeding to other experiments. HDAC inhibitor Trichstatin A (Sigma-
Aldrich, St. Louis, MO) was dissolved in DMSO (Sigma-Aldrich) at concentroation of 1 mM. 
Cells were cultivated in final concentration of 50ng/ml TSA for 3 days before proceeding to 
further analyses. 
Cloning strategy and generation of stable clones 
MCF7 cells were transfected with pcDNA-AREB6 plasmid (kind gift of T. Brabletz) using 
Magnet Assisted Transfection (IBA BioTAGnology, Göttingen Germany) according to 
manufacturer’s protocol. Cells transfected with pcDNA3 vector were used as control. Selection 
was done with 800 ug/ml G-418. 
For inducible expression of ZEB1 commercially available T47D Tet-on cells, expressing  high 
levels of the Tetracycline (Tet)-dependent transactivator, were used. To generate a ZEB1-
pTRE2pur expression cassette, full length cDNA of ZEB1 was excised from the pcDNA-AREB6 
plasmid (kind gift of T. Brabletz), treated with Klenow polymerase to create blunt-end fragments 
and ligated into the EcoRV restriction site of the dephosphorylated pTRE2pur response plasmid. 
For control, GFP-pTRE2pur expressing plasmid was generated. Full length EGFP was amplified 
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from the expression vector pEGFP-N1 (BD Biosciences) and cloned into the MCS of pTRE2pur. 
Afterwards, T47D Tet-on cells were transfected with the ZEB1-pTRE2pur and GFP-pTRE2pur 
constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, USA). Stably expressing cells were 
selected with 2.5 μg/ml Puromycine (Sigma, St Louis, MO, USA). Doxycycline at a concentration 
of 1μg/ml was used to induce T47D Tet-on cells. Clone 2 and clone 4 exhibited highest ZEB1 
levels and were used in present study. 
Antibodies 
Following Abs were used for immunoflourescence and immunoblotting experiments: mouse 
monoclonal Ab to E-Cadherin and ZO1 (BD Biosciences); goat polyclonal Ab to ZEB1 (ZEB-
E20) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); Actin (Sigma, St.Louis, USA); 
secondary Abs coupled to Alexa Fluor 488 (Molecular Probes Inc., Eugene, OR, USA); Texas 
Red or peroxidase (Jackson Laboratories, West Grove, PA, USA). 
RT- PCR 
Total mRNA and cDNA was prepared as described previously (Eger et al., 2005). PCR primers 
used for hKi67 were: forward 5'-ACCTCCAACCACCACACACT-3', reverse 5'-
TACAGTCGGCCCTCATGAAT-3' 
TUNEL Assay 
The TUNEL (terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end-labeling) 
assay was performed with the use of the In Situ Cell Death Detection Kit, TMR red (Roche 
Diagnostics, Mannheim, Germany), according to the manufacturer’s instructions. 
RNA inhibition experiments 
ZEB1-specific siRNA targets the sequence UGAUCAGCCUCAAUCUGCA of the human ZEB1 
mRNA, while SNAI1-specific siRNA targets CGAGGUGUGACUAACUAUG sequence of 
human SNAI1 mRNA. ZEB1-specific RNA oligonucleotides were purchased from RZPD 
(Deutsches Ressourcenzentrum für Genomforschung GmbH, Berlin, Germany), SNAI1-specific 
RNA from Ambion (Austin, TX, USA) and control siRNA Rhodamine and LaminA-specific 
siRNA were purchased from Qiagen (Qiagen, Hilden, Germany). RNA was transfected into 
MDAMB-231 cells using Oligofectamine (Invitrogen, Carlsbad, USA) according to the 
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manufacturers’ instructions. Cells were processed for matrigel invasion / trans-endothelial 
invasion assays, ECIS and ChIP analyses 3 days after transfection. 
Cell Invasion Assays 
To determine the cell invasion, BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, 
MA) containing an 8 micron pore size PET membrane with a thin layer of matrigel basement 
membrane matrix were used. 24-well tissue culture plate inserts coated with matrigel were re-
hydrated for 2 h in 37˚C RPMI in a humidified tissue culture incubator at 37˚C, 5% CO2 
atmosphere. Calculated numbers of cells for different experiment as shown in results section 
were plated on the insert in 0.5 ml of RPMI while 0.75 ml of RPMI + 10% FCS was added into 
the lower chamber. After incubation for 24 hours, non-invading cells were removed from the 
upper side of the membrane by scrubbing with a cotton swab. Cells at the lower side of 
membrane were fixed and stained with100% methanol and 1% Toluidine blue, respectively. 
Invading cells were photographed with axiovision microscope at 100X magnification and cells 
were counted in several fields of triplicate membranes. 
Electric cell–substrate impedance sensing (ECIS) 
To determine whether si-ZEB1 or si-SNAI1 affect transcellular resistance across endothelial 
cells, ECIS was used across HUVEC endothelial cell monolayer. ECIS electrode arrays (8W10E) 
were obtained from Applied BioPhysics. Each array slide consists of eight individually 
addressable wells with surfaces treated for cell culture. HUVEC (Human Umbilical Vein 
Endothelial Cells) were grown as a confluent layer covering each gold electrode. MDA-MB-231 
control, si-ZEB1, si-SNAI1 and si-ZEB1 & si-SNAI1 were stained with cell tracker and 10,000 
cells from each were seeded per chamber. Resistance/ Impedance were monitored for up to 180 
minutes. Cells were harvested from bottom and fluorescence was measured with PARADIGM™ 
Microplate Reader from Beckman. Normalization curves were made to analyze the ECIS results. 
ChIP assay 
ChIP assays were performed using human E-Cadherin promoter (forward 5’-
AACTCCAGGCTAGAGGGTCA-3’, reverse 5’-GGGCTGGAGTCTGAACTGA-3’) according 
to the instructions of the ChIP Assay Kit from Millipore (Eger et al., 2005). Antibodies used for 
ChIP assays include, anti-acetyl-histone H3 (Cat Nr. 06-599), anti-acetyl-histone H4 (Cat. Nr. 
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06-866), anti- dimethyl-histone H3 Lysine9 (Cat Nr. 07-521) and anti- dimethyl-histone H3 
Lysine27 (All from Millipore, Billerica, MA, USA) 
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4.2 Unpublished results 
4.2.1 Stable ZEB1 knock down using shRNA in MDA-MB-231 cells 
Knock-down of ZEB1 by transient RNA interference (RNAi) in cancer cells was sufficient to 
derepress E-Cadherin expression and restore cell to cell contacts, suggesting that ZEB1 is a key 
player in late stage carcinogenesis (Eger et al., 2005). In order to investigate the impact of ZEB1 
on cancer cell plasticity in more detail, I utilized stable RNAi strategy to achieve long term gene 
inhibition of ZEB1 in highly invasive cancer cells MDA-MB-231.  
 
Fig. 5: Transfection of shRNA in MDA-MB-231 cells. Oligos 953 and 2404 cloned in 
pSUPERIOR Neo+GFP vector were transfected in MDA-MB-231 cells and stained for GFP, 
ZEB1 and DAPI.  
We ordered specially desisgned shRNA oligos for ZEB1 gene from OligoEngine, and named 
them 953 and 2404 according to their starting position. I cloned them in pSUPERIOR Puro and 
pSUPERIOR Neo+GFP vectors (Oligoengine) and stably transfected in MDA-MB-231 cells 
using Lipofectamine 2000 (Invitrogen) (Fig.5). 
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Cells transfected with pSUPERIOR Puro were selected using 2.5 μg/ml Puromycine, while those 
transfected with pSUPERIOR Neo+GFP were selected with G418 (Geneticin®, Invitrogen) at a 
concentration of 1000 ug / ml for selection and 400 ug / ml for maintenance. Stable clones 
expressing these shRNAs were selected and tested for E-cadherin expression. Control MDA-
MB-231 cells express ZEB1 and little E-Cadherin, while clone expressing shZEB1 expressed no 
ZEB1 and E-Cadherin nicely localizing to the membrane as shown on IF and WB (Fig. 6A). But 
unfortunately, after a week ZEB1 started to show and E-Cadherin diminished from the 
membrane in the same clones. (Fig. 6B). 
              
Fig. 6: Stable clone expressing 953 oligo, cloned in pSUPERIOR Puro vector. (A) Oligo 953 
cloned in pSUPERIOR Puro vector were transfected in MDA-MB-231 cells and stained with 
ZEB1and E-Cadherin antibodies. (B) Same clone stained with same antibodies after a week. 
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4.2.2 Overexpression of ZEB1 domains as dominant negative approach 
We next planned to use dominant negative approach to stably downregulate endogenous ZEB1 
in MDA-MB-231 cells. Two zinc finger domains and the central homeobox domain were 
considered important, as the zinc fingers are involved in binding to DNA while parts around 
homeobox domain can engage other co-repressors etc. (Fig. 7). 
                             
Fig. 7: Schematic depiction of ZEB1 domains used as dominant negative. (A)The three 
domains are marked as NtZF (N-Terminal Zinc Finger), HOX (Homeobox Domain) and CtZF 
(C-Terminal Zinc Finger). (B)Binding of ZEB1 via its NtZF and CtZF to E-Cdherin promoter 
represses E-Cadherin expression involving other co-repressors. (C)These three domains can be 
overexpressed individually as potential dominant negatives of ZEB1. 
These individual domains were amplified and cloned into pENTR/D-TOPO entry vectors and 
shuttled to pcDNA-DEST40 vectors (Fig. 8). They were later utilized for stable transfections in 
COS7 and MDA-MB-231 cells using Lipofectamine 2000. Only CtZF was found to be expressed 
in both systems, other domains might be lethal for the cells as cells expressing them did not 
survive. MDA-MB-231 cells expressing CtZF were stained with E-Cadherin and ZO1 to see any 
effect but only a weak upregulation of E-Cadherin and a weak gain of epithelial features was 
observed (Fig. 9). 
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Fig. 8: Cloning strategy for generating dominant negatives of ZEB1. 
                                   
Fig. 9: Expression of ZEB1 domains. (A) The domains were over expressed in COS7 cells and 
western blot was produced using V-5 antibody. Only CtZF was expressed. (B) CtZF as expressed 
in MDA-MB-231 cells. CtZF was stained using His-Tag. E-Cadherin and ZO1 were co-stained 
but were found to be only slightly upregulated and localizing to the membrane. 
83 
 
4.2.3 ZEB1 in MCF7 cells expressing a variant of SNAI1 (MCF7-6SA) 
Zhou et al. published an MCF7 cell model in 2004, where they had stably expressed a mutated 
version of SNAI1. This variant of SNAI1 (Snail-6SA) abolishes the phosphorylations of two 
GSK3-β motifs that regulates its β-Trcp-mediated ubiquitination and subcellular localization 
respectively and therefore is much more stable and resides exclusively in the nucleus to induce 
EMT. We requested those constructs and cells to see the effect on ZEB1 expression. ZEB1 was 
found to be upregulated and expressed in the nuclei of MCF7cells expressing SNAI1 (Fig. 10A), 
hence indicating that SNAI1 induces ZEB1 expression in this model to bring about EMT. I 
knocked down ZEB1 and SNAI1 in these cells to see the effect on E-Cadherin level. 
Downregulation of both ZEB1 and SNAI1 resulted in only a slight increase and membrane 
localization of E-Cadherin (Fig. 10A). 
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Fig. 10: Mutated SNAI1 expressing MCF7 cells MCF7-6SA. (A) ZEB1 is expressed in SNAI1 
expressing MCF7 cells. (B)(C) siZEB1/siSNAI1 can upregulate the E-Cadherin expression 




5.1 ZEB1 represses epithelial determinants in cancer cells.  
E-cadherin is located in the adherens junctions, in epithelial cells, where it acts as a major cell-
cell adhesion molecule responsible for distinct epithelial cell polarity and strong intercellular 
interactions. Ecadherin downregulation is regarded as a central event in tumor progression and 
metastasis, as reduction of cell adhesion facilitates ability of tumour cells to migrate individually 
and invade. Despite several proposed genetic and epigenetic mechanisms, loss of E-cadherin is 
often attributed to transcriptional dysregulation. During the past few years, several transcription 
factors were identified as repressors of E-cadherin transcription. Among them, ZEB1 is 
increasingly considered important contributor to the process of malignant cancer progression. In 
present study, ZEB1 expression dramatically changed the intracellular localization of E-cadherin 
in epithelial breast cancer cell lines MCF7 and T47D. E-cadherin was exclusively distributed 
over the entire lateral membrane domain in parental cells. After two to three days of ZEB1 
expression, E-cadherin disappeared from the membrane and was mostly located in vesicular and 
rodlike structures within the cytoplasm. Simultaneously, these cells exhibited strongly reduced 
intercellular adhesion. Similar cytoplasmic structures of E-cadherin have been detected in 
fibroblastoid MDA-MB-231 cells, which express high amounts of endogenous ZEB1. From 
these observations and ZEB1 knock-down experiments (Aigner et al., 2007a; Eger et al., 2005)it 
is clear that ZEB1 represents a major regulator of epithelial plasticity in these breast cancer cells 
and  re-localization of E-cadherin back to the plasma membrane correlates with the loss of 
ZEB1. 
In addition, we show that, ZEB1 affects expression of several genes critically involved in 
epithelial polarity, supporting ZEB1’s regulatory role in EMT. Our approach for the 
identification of ZEB1 target genes was to selectively knockdown endogenous ZEB1, thus 
avoiding potential overexpression artefacts. Genes affected by ZEB1 include constituents of all 
junctional complexes located along the lateral membrane of epithelial cells and apical membrane 
proteins and epithelial Ig-domain adhesion molecules. Most interestingly, we identified ZEB1 as 
potent direct transcriptional repressor of the cell polarity genes Crumbs3, PATJ and HUGL2, as 
demonstrated by ChIP and reporter assays. Loss of epithelial cell polarity proteins causes severe 
defects in epithelial polarity, which is a primary diagnostic mark for malignant carcinomas. 
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Their functional loss also enhances tumour cell proliferation and invasion (Bilder, 2004; Brumby 
and Richardson, 2005). Hence, ZEB1-mediated repression of Crumbs3, PATJ and HUGL2 in 
cancer cells may affect multiple aspects of normal epithelial physiology favouring cancer 
progression, invasion and metastasis. 
5.2 The transcription programmes of different E-cadherin repressors  
Like ZEB1 the E-cadherin repressors SNAI1, SNAI2, SIP1 and E47 also modulate epithelial 
architecture and induce EMT (De Craene et al., 2005b; Peinado et al., 2004b). However, the 
specific contributions of these repressors to EMT in development and tumour progression are 
poorly understood. First insights have been gained from recent microarray studies, in which 
specific transcription programmes were determined by overexpression of these proteins in 
human colon cancer or Madin–Darby canine kidney cells (De Craene et al., 2005a; Moreno-
Bueno et al., 2008; Vandewalle et al., 2005). Despite the different cell lines and experimental 
set-ups used, a few important conclusions can be drawn from the synopsis of the four data sets. 
First, among the E-cadherin repressors ZEB1 showed the strongest negative effect on epithelial-
specific transcription. Second, none of the other repressors was capable of repressing cell 
polarity genes. Third, the related repressors ZEB1 and SIP1 may regulate different sets of 
junctional genes. 
Interestingly, SNAI1 is not always sufficient to repress E-cadherin, as demonstrated in DLD-1 
colon cancer cells overexpressing SNAI1 (De Craene et al., 2005a), and in our previous studies, 
revealing that SNAI1 expression did not correlate with E-cadherin repression in human breast 
cancer cell lines (Eger et al., 2005). In present study, we show that knockdown of SNAI1 was 
not sufficient to activate expression of E-cadherin, Crumbs3 or HUGL2 in MDA-MB-231 cells. 
(Shirakihara et al., 2007)has also demonstrated that ZEB family proteins are essential for 
repression of E-cadherin expression by TGFβ and SNAI1 is not involved in the repression of E-
cadherin expression in NMuMG cells. Yet, numerous studies have shown a negative impact of 
SNAI1 on E-cadherin expression and epithelial differentiation (Batlle et al., 2000; Cano et al., 
2000; Palmer et al., 2004; Peinado et al., 2004b; Pena et al., 2006; Pena et al., 2005). In addition, 
we found that overexpressed SNAI1 also affected Crumbs3 and HUGL2 promoter activity, 
indicating SNAI1’s intrinsic capability to affect these genes in breast cancer cells. Therefore, 
overall expression levels of the E-cadherin repressors and the availability of cofactors may 
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determine target gene specificity and their final impact on EMT, tumour progression and 
metastasis (Pena et al., 2006).  
5.3 ZEB1 negatively regulates the proliferation rate 
The finding that ZEB1 can strongly reduce the proliferation rate of cancer cells is in line with 
models which consider cancer cell invasion and proliferation as mutually exclusive events 
(Brabletz et al., 2005a; Brabletz et al., 2005b). It has been speculated that the profound 
morphological changes during EMT, such as those observed during embryonic gastrulation or 
during tumor cell invasion might be incompatible with high proliferation rates (Foe, 1989; Jung 
et al., 2001).  Interestingly, also the overexpression of SNAI1 can attenuate cell cycle 
progression. Moreover, SNAI1 can confer resistance to cell death induced by the withdrawal of 
survival factors or by pro-apoptotic signals (Vega et al., 2004).  
5.4 ZEB1 as a regulator of invasion potential  
We have shown that dedifferentiated breast cancer cell line MDA-MB-231 in which RNAi-
mediated knock-down of ZEB1 led to upregulation of a set of cell junctional genes as well as cell 
polarity genes (Aigner et al., 2007a; Aigner et al., 2007b). These data suggest that ZEB1 can 
transcriptionally reprogram the epithelial cell signature towards a more mesenchymal type. We 
used the same highly invasive breast cancer cell line MDA-MB-231 and monitored their 
invasion potential with siRNA mediated knock down of ZEB1 and SNAI1 alone or in 
combination, in various sophisticated ways. All methods used, gave us similar outcome, i.e.  
siRNA ZEB1 alone reduced the invasion potential of MDA-MB-231 cells quite efficiently. It is 
interesting to note that siRNA SNAI1 alone was only sufficient to bring a smaller change to the 
invasive potential and the result of combined siRNA ZEB1 and SNAI1 was similar to siRNA 
ZEB1 alone. So, from this finding it is clear that ZEB1 alone is sufficient for the control of 
invasiveness of MDA-MB-231 cells. There are some studies emphasizing role of SNAI1 in 
migration and invasion (Fabre-Guillevin et al., 2008; Olmeda et al., 2007). The second thing that 
we checked in these experiments was invasion potential of ectopically E-Cadherin expressing 
MDA-MB-231 cells. Ectopic expression of E-Cadherin was not sufficient to induce epithelial 
genes and barely affected the motility of MDA-MB-231 cells (Aigner et al., 2007b). Similarly, 
ectopically expressed E-Cadherin could not block the invasiveness of MDA-MB-231 cells. 
Hence we found that ZEB1 is the key factor controlling the invasive properties in MDA-MB-231 
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cells. These findings are in line with immunohistochemical detection of ZEB1 at the tumor-host 
interface in colorectal cancer specimens, accompanied by nuclear β-catenin and reduced 
cytokeratin, strongly indicating dedifferentiation and tumor cell invasion (Aigner et al., 2007b). 
Furthermore, ZEB1 is found to be the main modulator of the basement membrane (BM) 
components encoded by genes LAMA3, COL4A2 and LAMC2, and it generates a local, 
transient loss of the BM at the invasive front (Spaderna et al., 2006). ZEB1 therefore seems to be 
a major constituent allowing tumor cell dissemination at these invasive fronts.  
5.5 Involvement of chromatin modifications through ZEB1 induce E-Cadherin repression 
During recent years, a series of experimental studies have established a direct role for ZEB1 in 
the repression of E-cadherin (Eger et al., 2005). However, in addition to direct inhibition of E-
cadherin transcription via binding to the E-boxes (CACCTG) present in the E-cadherin promoter, 
the transcriptional suppressive function of ZEB1 may be linked to the recruitment of histone 
deacetylases to gene promoters (Ohira et al., 2003; Yang et al., 2009; Yang et al., 2007). ZEB1 
has been shown to associate with the co-repressors CtBP1 and CtBP2 (Furusawa et al., 1999; 
Grooteclaes and Frisch, 2000; Postigo and Dean, 1999; Zhao et al., 2009), which in turn are 
capable of interacting with histone-deacetylases (HDACs) (Chinnadurai, 2002; Sundqvist et al., 
1998). In this way a specific multiprotein complex is established at the promoter of the E-
cadherin gene, which leads to covalent modifications of histones and DNA, resulting in promoter 
specific chromatin condensation and repression of transcription.  In addition, our lab investigated 
interaction partners of ZEB1 and found JMJD2A which also is known to interact with Class I 
HDAC’s (Eger, A. unpublished data).  In the present study we were able to show the epigenetic 
modifications on E-Cadherin promoter, dependent on ZEB1 transcription factor. siRNA 
mediated ZEB1 knock down in MDA-MB-231 cells resulted in loss of suppression and thus 
actively transcribed E-Cadherin, as indicated by loss of repressive marks H3K9me2 and 
H3K27me2 and simultaneous acquisition of Acetylated H3 and H4, the markers of actively 
transcribed genes.  
5.6 ZEB1 and human cancer progression in vivo  
To analyse the role of ZEB1 in human cancer in vivo we tested ZEB1 expression in colon and 
breast cancer specimens. In colon cancer, ZEB1 was upregulated at the tumour–host interface 
and was accompanied by epithelial dedifferentiation and tumour cell invasion. In invasive ductal 
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carcinomas of the breast, ZEB1 upregulation correlated with epithelial dedifferentiation and 
undifferentiated lobular breast tumours expressed ZEB1 in a large proportion of cells. ZEB1 was 
also highly expressed in tumour-associated stroma cells. It is unclear whether ZEB1-positive 
stromal fibroblasts may be derived from epithelial cancer cells through a bona fide ZEB1-
dependent EMT in vivo. 
Several recent reports provide supporting evidence for a role of ZEB1 in the malignant 
progression of different cancer types. (1) In non-small cell lung cancer and in renal cell 
carcinomas ZEB1 repressed E-cadherin expression in response to cyclooxygenase-2 activation or 
hypoxia-inducible factor-1 mediated signalling, respectively (Dohadwala et al., 2006; 
Krishnamachary et al., 2006). (2) In high-grade endometrioid adenocarcinomas and other 
aggressive types of uterine cancers, ZEB1 was strongly expressed in E-cadherin negative 
carcinoma cells (Spoelstra et al., 2006). (3) In colon tumours, ZEB1 repressed the expression of 
specific laminin genes and this transient basement membrane loss correlated with increased 
distant metastasis and poor patient survival (Spaderna et al., 2006). Likewise, an inverse 
correlation of ZEB1 and E-cadherin levels was observed in colon tumours lacking Snail1 (Pena 
et al., 2005). 
The molecular cues that induce ZEB1 expression in particular cancer settings or in particular 
tumour areas are still elusive. Candidates for ZEB1 inducers are TGFb, tumour necrosis factor-a 
(TNF-a) and Wnts, which are often excessively produced by different tumour-associated stroma 
cells (Chua et al., 2007; Nishimura et al., 2006; Ohira et al., 2003). One attractive hypothesis is 
that tumour infiltrating macrophages, which are abundantly detected at the tumour–host 
interface, express cytokines that may induce ZEB1 expression (Condeelis and Pollard, 2006). 
In summary, the data of this study provide strong evidence for a key function of ZEB1 in late-
stage cancer progression. Large-scale tumour studies with well documented clinical records will 
be critical to determine whether ZEB1 can be used as a prognostic parameter to predict 
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